1. sports
2. martial arts

SEVENTEENTH ANNUAL SCIENTIFIC MEETING
HONG KONG UROLOGICAL ASSOCIATION
2011
SEVENTEENTH ANNUAL SCIENTIFIC MEETING
HONG KONG UROLOGICAL ASSOCIATION
08:30 – 17:00
6 November 2011
Sheraton Hong Kong Hotel & Towers
Kowloon
HONG KONG S.A.R.
HONG KONG UROLOGICAL ASSOCIATION
Hong Kong Urological Association was incorporated on 11th
September 1987.
The main objectives of the Association are:

To promote the interest in and a better understanding of Urology in
Hong Kong;

To provide a venue for discussion of problems related to Urology;

To improve and set the standard of urological care in Hong Kong;

To provide a means of liaison with workers in Urology in other
parts of the world;

To advise and provide information on postgraduate urological
training;

To collect and disseminate information regarding members of the
Association and information of any event or happening.
To achieve the objectives, monthly council meeting is held to plan,
organise, implement and review the activities of the Association.
Regular academic meetings, which include case presentations, topic
discussions and talks by invited speakers, are held monthly. Renowned
overseas speakers have been invited to deliver lectures on subjects of
special interest. Seminars, workshops, education programmes and talks
to the public, general practitioners and other associations have been
organised to enhance communication with the community and other
medical specialties.
CONTENT
Message from the President ……………….…………….………............
1
Council, Subcommittees, Sections ……………….……….………........
3
Past Presidents ………………….………………………….…………...
6
Member List ………………….…………………………..………………
7
Members’ Publications ………………………………………………….
12
Invited Speakers …………….………………………………….…........
15
Programme-At-A-Glance …………….…………………………….........
17
Congress Venue ...….…………………...…………………………..
18
Scientific Programme…..…………….………………………………….
20
Family Physician Symposium ...............……….………………............
22
Schedule of Oral (Free Paper) Sessions …………….…………………
23
Schedule of Moderated Poster (Free Paper) Sessions …………………
31
Schedule of Nursing Oral Free Paper Session ………………………..…
34
Abstracts for Oral (Free Paper) Sessions ………………………….……
35
Abstracts for Moderated Poster (Free Paper) Sessions ……….………… 55
Abstracts for Nursing Oral (Free Paper) Session ……………..…...........
64
Exhibition Floor Plan ……………………………….........……………
66
Congress Sponsors Directory …………………………………………… 67
Acknowledgements ……………………………….........……………...
79
Message from The President
This year we are deeply honored to have two distinguished guests.
Dato’ Professor Hui Meng TAN from Malaysia will deliver the State-ofthe-Art Lecture on “Men’s Health in Asia: the Role of Urologist”, and also
the Keynote Lecture on “Testosterone Replacement Therapy in Asian
Men”. Professor Tony WU, Secretary General of the 2010 Asian Congress
of Urology, will deliver the UAA Lecture. He will speak on “Prostate
Cancer in Taiwan”.
Dato’ Professor TAN and Professor WU have both kindly agreed to
be the adjudicators for the Best Oral Free Paper. This year we have 29
abstracts submitted for presentation. The authors of the abstracts include
not only our trainees and young urologists, but also urologists from
mainland China. Thanks to the hard work of the three panelists, Professor
Sidney YIP, Dr CW MAN and Dr Simon LEUNG, 20 abstracts were
selected for oral presentation and 9 selected for poster presentation.
This is the second year that HKUA’s Annual Scientific Meeting has a
Family Physician Symposium. The Council believes that this is the best
opportunity to promote urological knowledge among our family physician
colleagues, allowing them to have an in-depth understanding of our
achievement. I thank Dr Simon LEUNG and the members who have kindly
agreed to be speakers of this symposium.
As for the Urology Nursing Symposium, this year we also have
presentations from urology nurses from Macau. I am sure that this will
provide an additional means of sharing knowledge and experience among
colleagues in Asian regions.
The Council expresses its sincere gratitude to our industrial partners
for their generous support and participation. Their display of the most
recent advances in equipment and drugs is well worth visiting. As a bonus,
one would get a chance to win a special HKUA edition of iPad2 which
cannot be obtained elsewhere. The Council hopes that our industrial
1
partners would be able to support our mega
partners would be able to support our mega event next year, the 23rd Video
Urology World Congress, 8-11 November 2012, co-organised by Hong
Kong Urological Association, Hong Kong Society of Endourology, and
Division of Urology, the Chinese University of Hong Kong.
I thank our Council Members, Subcommittee Members and others
for their time and their hard work in preparing for this ASM. I am deeply
impressed by our members who always give me a positive answer
whenever I ask them for help. Last but not least, I wish you enjoy today’s
program. This Meeting will only be successful with your active
participation and support. Thank you.
CHU Sau Kwan Peggy
2
COUNCIL 2010 – 2012
Dr CHU Sau Kwan Peggy
President
Dr CHAN Wai Hee Steve
Honorary Secretary
Dr FAN Chi Wai
Honorary Treasurer
Dr HO Kwan Lun
Council Member
Dr HOU See Ming Simon
Council Member
Dr MAH Soo Fan Ida
Council Member
Dr SO Hing Shing
Council Member
Professor YIP Kam Hung Sidney
Council Member
Dr YIU Ming Kong
Ex-Officio
3
SUBCOMMITTEE EXECUTIVES
Education Subcommittee
Dr MAN Chi Wai (Convenor)
Dr WONG Tak Hing Bill (Co-convenor)
Dr TAM Po Chor (Co-convenor)
Professor YIP Kam Hung Sidney (Co-convenor)
Dr YIU Ming Kwong (Co-convenor)
Dr CHAN Wai Hee Steve
Dr CHEUNG Ho Yuen
Dr HO Lap Yin
Dr HUNG Hing Hoi
Dr LEUNG Yiu Lam Simon
Dr NG Chi Fai
Dr NGAI Ho Yin
Dr TSU Hok Leung James
Information Technology Subcommittee
Dr SZETO Shek Petrus (Convenor)
Dr CHAU Hin Lysander
Dr MA Wai Kit
Dr TAI Chi Kin Dominic
Dr WONG Chun Wing Simon
Newsletter Subcommittee
Dr CHU Sau Kwan Peggy
Dr CHAN Wai Hee Steve
Dr WONG Chun Wing Simon
Welfare Subcommittee
Dr MAH Soo Fan Ida (Convenor)
Dr FUNG Tat Chow Berry
Dr LAM Kin Man
Urology Nurse Chapter
Ms. CHIU Lai Ping Grace (Chairperson)
Ms. WONG Siu Wan Arale (Hon Treasurer)
Ms. YUNG Wing Yee (Hon Secretary)
Ms. CHOW Hiu Ying (Welfare)
Mr. CHING Lok Sang Jan (Information Technology)
Ms. KAM Yuen Ching Veron (Education)
4
SUBSPECIALTY SECTIONS CO-ORDINATORS
Section of Andrology
Dr MAK Siu King
Dr NGAI Ho Yin
Dr WONG Wai Sang
Section of Endourology
Dr CHAN Wai Hee Steve
Dr FAN Chi Wai
Dr LI Shu Keung
Professor YIP Kam Hung Sidney
Section of Female Urology
Dr CHEUNG Ho Yuen
Dr CHU Sau Kwan Peggy
Dr MAH Soo Fan Ida
Section of Paediatric Urology
Dr SZETO Shek Petrus
Dr TO Kim Chung
Dr YIU Ming Kwong
Section of Uro-oncology
Dr FUNG Tat Chow Berry
Dr HO Lap Yin
Dr WONG Tak Hing Bill
Section of Young Urologist
Dr CHAN Shu Yin Eddie
Dr NG Chi Fai
Dr TSU Hok Leung James
5
PAST PRESIDENTS
1987 – 1994
Dr LEONG Che Hung
1994 – 1996
Dr CHAN Yau Tung Andrew
1996 – 1998
Dr FENN John
1998 – 2000
Dr YIU Tim Fuk
2000 – 2002
Dr WONG Tak Hing Bill
2002 – 2004
Dr NGAI Loi Cheong Rudolph
2004 – 2006
Dr MAN Chi Wai
2006 – 2008
Dr WONG Wai Sang
2008 – 2010
Dr YIU Ming Kwong
6
MEMBER LIST
Full Members
7
Dr AU Wing Hang
Dr HO Kwok Kam
Dr CHAN Chi Kwok
Dr HO Kwan Lun
Dr CHAN Kwok Keung Sammy
Dr HO Lap Yin
Dr CHAN Lung Wai
Dr HO Man Tzit Kossen
Dr CHAN Ning Hong
Dr HO Shing Chee Sammy
Dr CHAN Shu Yin Eddie
Dr HO Yu Cheung
Dr CHAN Siu Hung Lawrence
Dr HOU See Ming Simon
Dr CHAN Tsz Yeung
Dr HUNG Hing Hoi
Dr CHAN Wai Hee Steve
Dr KAN Chi Fai
Dr CHAN Yau Tung Andrew
Dr KOO C G George
Dr CHAU Hin Lysander
Dr KWOK Ka Ki
Dr CHENG Chi Wai
Dr KWOK Kwan Yee David
Dr CHEUNG Fu Keung
Dr KWOK Shan Chun
Dr CHEUNG Ho Yuen
Dr KWOK Tin Fook
Dr CHEUNG Man Chiu
Dr LAM Kin Man
Dr CHU Sai Man Simon
Dr LAM Siu Hung Joseph
Dr CHU Sau Kwan Peggy
Dr LAM Yiu Chung
Dr CHU Tin Yu
Dr LAU Ban Eng
Dr CHU Wing Hong
Prof LAU Wan Yee Joseph
Dr CHUI Ka Lun
Dr LAU Wing Chu
Dr CHUNG Yeung Vera
Dr LAW In Chak
Dr FAN Chi Wai
Dr LEE Chan Wing Francis
Dr FENN Benjamin
Dr LEONG Che Hung
Dr FENN John
Dr LEUNG Yiu Lam Simon
Dr FU Kam Fung Kenneth
Dr LI Cheuk Man James
Dr FUNG Tat Chow Berry
Dr LI Shiu Ki Raymond
Dr HO Chun Kit Peter
Dr LI Shu Keung
Full Members (Cont.)
Dr LIU Hin Wing Peter
Dr TAI Chi Kin
Dr LIU Pak Ling
Dr TAM Po Chor
Dr LO Hak Keung
Dr TEOH Sim Chuan Timothy
Dr LO Ka Lun
Dr TO Kim Chung
Dr LO Kwong Yin Richard
Dr TSU Hok Leung James
Dr LOK Wang Yip
Dr VELAYUDHAN Venu
Dr MA Chi Min
Dr WONG Bok Wai Byron
Dr MA Wai Kit
Dr WONG Chi Ho James
Dr MAH Soo Fan Ida
Dr WONG Chun Wing
Dr MAK Siu King
Dr WONG Kwok Kee
Dr MAN Chi Wai
Dr WONG Hon Ming
Dr NG Chi Fai
Dr WONG Kwok Tin Martin
Dr NG Chung On
Dr WONG Man Keung
Dr NG Man Tat
Dr. WONG Ming Ho, Edmond
Dr NG Siu Kai
Dr WONG Shu Hong
Dr NG Sung Man Anthony
Dr WONG Tak Hing Bill
Dr NGAI Ho Yin
Dr WONG Wai Sang
Dr NGAI Loi Cheong Rudolph
Dr WONG Yuk Ting
Dr NGAN Hin Kay John
Dr WU Ho Hon
Dr ONG Lilian Lina
Prof YIP Kam Hung Sidney
Dr PAULOSE N M
Dr YIP Siu Keung
Dr QUE Bon We Manuel
Dr YIP Yu Lap
Dr SHUM Ding Ping John
Dr YIU Ming Kwong
Dr SIT King Ching Angela
Dr YIU Tim Fuk
Dr SO Chun
Dr YU Cheong
Dr SO Hing Shing
Dr YU Ho Yam Henry
Dr SUN Wai Ho
Dr YUE Ping Hoi Thomas
Dr SZETO Shek Petrus
Dr YUNG Yee Ping
Dr SZETO Yiu Kwai
8
Ordinary Members
Dr CHAN Cheuk Lok
Dr LO Ting Kit
Dr CHAN Chun Ki
Dr MA Kwok Kuen
Dr CHAN Hoi Chak Wilson
Dr MAK Chu Kay
Dr CHAN Kwun Wai
Dr MAN Ka Ki
Dr CHAU Kai Fung Kenneth
Dr MO Pan Herbridge
Dr CHENG Cheung Hing
Dr NG Chi Man
Dr CHENG HON KUEN
Dr NG Tsui Lin Ada
Dr CHEUNG Chi Kin Arthur
Dr NGO Chang Chung
Dr CHEUNG Foon Yiu
Dr SHUM Chung Nin
Dr CHEUNG Man Hung
Dr TAM Ho Man
Dr CHIU Ka Fung Peter
Dr TEOH Yuen Chun Jeremy
Dr CHIU Yi
Dr TSANG Chiu-fung
Dr CHO Chak Lam
Dr TSE Po Ki Teresa
Dr CHOW Chi Wai Kelvin
Dr TSUI Tsun Miu
Dr CHU Ho Cheung
Dr WONG Chi Tak Danny
Dr CHU Yip
Dr WONG Ka Wing
Dr HO Kwok Leung Franklin
Dr WONG Kwok Kei
Dr HO Brian Sze Ho
Dr WONG Sin Man
Dr IP Chi Ho
Dr YEE Chi Hang
Dr IP Fu Keung
Dr YEUNG Hip Wo Victor
Dr LAM Yui
Dr YEUNG Kwok Fai Benson
Dr LAU Hiu Yan Stephanie
Dr YEUNG Suet Ying
Dr LAW Man Chung
Dr YIP Chi Pang
Dr LAW Yuk
Dr YIU Lo Ramon
Dr LEE Yue Kit
Dr YIP Siu Man
Dr LEUNG Ho Kai Phillip
9
Dr LI Ka Ho
Retired Members
Dr LI Siu Kei
Dr CHAN Siu Foon Peter
Dr LO Cho Yau
Dr WATT Chung Yin
Associate Members
Dr CHAN Tai Ip
CHOI Hei Men Lois
Dr DE CARVALHO R Vitalino
CHOI Ming Yee
Dr GU Di
CHONG Wing Chi
Dr HAN Ping
CHOW Hiu Ying
Dr HO Son Fat
CHOW Mei Ling
Dr IAN Lap Hong
CHU Sau Lan
Dr LAU Heng Loi
DAI Lai Man
Dr LI Kin
FONG Im Ha
Dr MAHAWONG Phitsanu
HEUNG Ying Ho
Dr PUN Wai Hong
HO Fung Yee
Dr TAN Kaw Hwee
HO Ka Lai Kairy
Dr TONG Sut Sin
IP Alan
Dr TSE Man Kin
KAM Yuen Ching
Dr WU Peng
KONG Chung Yan
CHAN Ka Ki Cherry
KWAN Wai Fan
CHAN Kam Yan
LAI Soi In
CHAN Kuong Wa
LAM Choi Hing
CHAN Pak Tong
LAM Lai Fong
CHAN Sau Lan Anita
LAM Shuk Yee
CHAN Sau Ying
LAM Sin Ha Grace
CHAN Siu Hung Julie
LAM Yuen Ha
CHAN Wai Chi Winnie
LAM Yuk Chu
CHAU Fung Yee Cherry
LAU Ka Wai
CHENG Hau Ying
LAU Wai Man
CHEUNG Lee Yuet Ngor
LEE Kwai Fong
CHEUNG Loi Kam Christina
LEUNG Ka Ki Larry
CHEUNG Mei Fong Emily
LEUNG Mei Nok
CHEUNG Yi Ki
LEUNG Pui Ping Sarah
CHING Lok Sang Jan
LEUNG Sau Fan Doris
CHIU For Shing
LEUNG Suet Yee
CHIU Lai Ping Grace
LEUNG Sze Nok
10
Associate Members (Cont.)
LEUNG Tsui Wah
TSE Yee Man
LEUNG Wing Yee Helen
TSE Yuk Ling
LEUNG Yuet Mui
TSUI Chiu On
LI Ling Wai
VONG Fong Leng
LI Miu Ling
WAT Ngun Ling Daisy
LING Yik Mei Canmei
WONG Hiu Wan
LIU Man Yee
WONG Ka Wai
LO Kit Ching Salina
WONG Lai Fong
LO Yuk Lin
WONG Lai Ying
LUI Kam Man
WONG Mei Kwan
LUI Yuen Ling Camilla
WONG Miu Ping
LUK Mun Yi
WONG Pui Chun
MA Ying Yu
WONG Pui Shan
MAK Wai Han
WONG Siu Wan Arale
MAK Yee Ching
WONG Suk Kum Do Do
NG Suk Ching
WONG Wan Ting
PANG Wai Chung Joan
WOO Ching Tak
SAE Lo Kittisak
WOO Yee Shan
SI Pek
WU Pui Hing
SIU Pui Ching
YAN Ka Kwan
SO Ah Tak
YAN Kit Hing
SO Hing Luen
YAU Kit Ling Helen
SO Oi Yee
YEUNG Shirley
SUEN Sui Lan
YIM Mei Sum
SZE Siu Chai Bonnie
YU Mei Lan
TAM Chung Ying
YU Pui Ling
TANG Chi Chiu Kevin
YU Wai Ling
TANG Man Yee Lois
YUEN Hon Kwan
TO Hoi Chu
YUEN Ka Ling
TO Man Chung
TSANG Wai Mei Joey
11
Members’ Publications (1 July 2010 – 30 June 2011)
Synovial Sarcoma of The Kidney: A Report Of 4 Cases With Pathologic
Appraisal And Differential Diagnostic Review
Anal Quant Cytol Histol. 2010 Aug; 32(4):239-45. Review. PubMed PMID:
21434526
YS Tan, LG Ng, SK Yip, MH Tay, AS Lim, SL Tien, L Cheng, PH Tan
Early Experience of Adjustable Transobturator Male System (ATOMS)
Operation for Post Radical Prostatectomy Stress Incontinence in a Local
Hospital in Hong Kong
Int J Urol 2010, 17, Suppl 1: A154
TY Chan, C Yu, KM Lam, SK Chu, CW Man
Thermo-Expandable Titanium-Nickel Spiral Ureteric Stent for Ureteric
Stricture: Early Experience in a Local Hospital in Hong Kong
Int J Urol 2010, 17, Suppl 1: A173
TY Chan, C Yu, KM Lam, SK Chu, CW Man
Infectious Complication after Transrectal Ultrasound - Guided Prostate
Biopsies: A Review of 1525 cases
Int J Urol 2010, 17, Suppl 1: A205
CH Cheng, CH Yee, Y Chiu, WF Lee, HC Chan, CK Tai, C Yu, HS So, SK Chu, CW
Fan, MK Yiu, V Velayudhan, CW Man
Does Previous Endoscopic Urethrotomy affect Results of Anastomotic
Urethroplasty: Hong Kong Experience?
Int J Urol 2010, 17, Suppl 1: A205
CH Cheng, MH Cheung, HL Tsu, SWH Chan, ISF Mah, PSK Chu, CW Man, B
Wong
Once-Daily 120mg Sublingual Desmopressin in the Treatment of Nocturia
in Male Patients with Benign Protatic Hyperplasia
Int J Urol 2010, 17, Suppl 1: A151
ACK Cheung, TYC Lam, PSK Chu, CW Man
Does Delay in Diagnosis affect Outcome in Iatrogenic Ureteric Injury: A
Review of 21 Cases
Int J Urol 2010, 17, Suppl 1: A254
ACK Cheung, PSK Chu, CW Man
12
Salvaging Post Renal Transplant Ureteric Stricture by Boari Flap: Review
of 2 Cases
Int J Urol 2010, 17, Suppl 1: A172
MH Cheung, PSK Chu, CW Man
Preliminary Results in using Tension Adjustable Mesh for Female Stress
Urinary Incontinence (SUI)
Int J Urol 2010, 17, Suppl 1: A183
C Yu, SK Chu, CW Man
Effect of Daily 0.5mg Oral Dutasteride on Prostate Volume Reduction in
Chinese Men with Symptomatic Benign Prostatic Hyperplasia
Int J Urol 2010, 17, Suppl 1: A194
C Yu, SK Chu, CW Man
Editorial Comment to Does Performance of Robot-Assisted Laparoscopic
Radical Prostatectomy Within 2 Weeks After Biopsy Affect The Outcome?
Int J Urol. 2011 Feb; 18(2):146-7. doi: 10.1111/j.1442-2042.2010.02679.x. PubMed
PMID: 21272084.
SK Yip
Pneumovesicum Approach to En-Bloc Laparoscopic Nephroureterectomy
with Bladder Cuff Excision for Upper Tract Urothelial Cancer: Midterm
Oncological Results
J Endourol. 2011 Apr; 25(4):611-4. Epub 2011 Feb 25. PubMed PMID: 21351884.
SK Mak, CF Ng, ES Chan, SK Yip, CW Cheng, WS Wong
Robot-Assisted Radical Prostatectomy (RARP) in Princess Margaret
Hospital
Surg Practice 2011, 15, Suppl: S1
KC To, WK Ma, TY Chu, PL Liu, MK Yiu
The Effect of Ketamine Use on Urinary System and Factors Associated –
From Symptoms to Urodynamic Change and Biochemical Impairment
Surg Practice 2011, 15, Suppl: S11
CM Ng, WK Ma, KC To, MK Yiu
13
Associations of Obesity and Results of Transrectal Biopsy of Prostate
Surgical Practice 2011, 15, Suppl: S1
PKF Chiu, ACK Cheung, SK Chu, CF Ng
Neoadjuvant Chemotherapy for Locally Advanced and/or Regionally
Metastatic Bladder Cancer in Chinese: Tuen Mun Hospital Experience
Surgical Practice 2011, 15, Suppl: S6
CL Cho, KC Lee, CS Wong, SK Chu, Y Tung, CW Man
Distinct DNA Methylation Epigenotypes in Bladder Cancer from Different
Chinese Sub-Populations and Its Implication in Cancer Detection Using
Voided Urine
BMC Med Genomics. 2011 May 20; 4:45. PubMed PMID: 21599969; PubMed
Central PMCID: PMC3127971
PC Chen, MH Tsai, SK Yip, YC Jou, CF Ng, Y Chen, X Wang, W Huang, CL Tung,
GC Chen, MM Huang, JH Tong, EJ Song, DC Chang, CD Hsu, KF To, CH Shen,
MW Chan
Zoledronic Acid to Prevent Bone Loss in Chinese Men Receiving Androgen
Deprivation Therapy for Prostate Cancer
Asia Pac J Clin Oncol. 2011 Jun; 7(2):168-73. doi:
7563.2011.01388.x. PubMed PMID: 21585697
CH Yee, CF Ng, AY Wong, CK Chan, SM Hou, SK Yip
10.1111/j.1743-
Using Urine Microscopy and Cytology for Early Detection of Bladder
Cancer in Male Patients with Lower Urinary Tract Symptoms
Int Urol Nephrol. 2011 Jun; 43(2):289-94. Epub 2010 Nov 4. PubMed PMID:
21053072.
ES Chan, CF Ng, SM Hou, SK Yip
Medical Expulsive Therapy Using Alfuzosin for Patient Presenting With
Ureteral Stone Less Than 10 Mm: A Prospective Randomized Controlled
Trial
International Journal of Urology (2011) 18, 510–514 doi: 10.1111/j.14422042.2011.02780.x
LH Chau, DCK Tai, BTC Fung, JCM Li, CW Fan, MKW Li
14
UAA LECTURE
"Prostate Cancer in Taiwan”
Professor Tony Tong-Lin WU, MD, EMBA
Chief, Department of Surgery, Kaohsiung Veterans General Hospital
Associate Professor of Urology
National Yang-Ming University, School of Medicine,
Taipei Medical University
TAIWAN
15
STATE-OF-THE-ART LECTURE
“Men’s Health in Asia: The Role of Urologist”
KEYNOTE LECTURE
“Testosterone Replacement Therapy in Asian Men”
Dato’ Professor Hui Meng TAN, FRCS(Edin), FRCPS(Glasg)
Consultant Urologist
Adjunct Professor, Faculty of Medicine, University of Malaya
Secretary General, Asia Pacific Society for Study of the Aging Male
Board of Directors, SSM,ISMH and ISSAM
MALAYSIA
16
PROGRAM AT A GLANCE
66 NNO
OVVEEM
MBBEERR 22001111,, SSUUNNDDAAYY
07:00 – 08:30
Exhibition Set-up
08:30  08:50
Reception / Registration / Trade Exhibition
08:50  09:00
Welcome Address
UAA Lecture
3/F Ballroom C
09:00 – 09:30
09:30 – 10:00
3/F Tang Room II
“Prostate Cancer in Taiwan”
View of Posters /
Trade Exhibition
State-of-the-Art Lecture
“Men’s Health in Asia: The Role of Urologist”
10:00 – 10:30
Coffee Break / Trade Exhibits
CONCURRENT SESSIONS
3/F Ballroom C
3/F Tang Room I
10:30 – 11:25
Oral (Free Paper) Session I
Moderated Poster (Free Paper) Session I
11:25  12:20
Oral (Free Paper) Session II
Moderated Poster (Free Paper) Session II
12:20 – 13:45
Lunch / Trade Exhibits
PLENARY SESSIONS
3/F Ballroom C
13:45 – 14:40
14:40– 15:35
15:35 – 16:15
16:15  16:45
Oral (Free Paper)
Session III
Oral (Free Paper)
Session IV
CONCURRENT SESSIONS
3/F Tang Room I
Urology Nursing
Symposium I
Urology Nursing
Symposium II
Coffee Break / Trade Exhibition
1330  1500
1500  1530
1530  1700
Keynote Lecture
“Testosterone Replacement Therapy in Asian Men”
16:45 – 16:55
Prize Presentations and Lucky Draw
16:55  17:00
Closing Remarks
17
4/F Ming Room II
Family Physician
Symposium Session I
Coffee Break / Trade
Exhibits
Family Physician
Symposium Session II
3rd Floor
Ballroom C
UAA Lecture
State-of-Art Lecture
Keynote Lecture
Oral (Free Paper) Sessions
Ballroom A & B
Exhibition Venue I
Tang Room I
Moderated Poster (Free Paper) Sessions
Urology Nursing Symposia
Tang Room II
Scientific Posters Display
Exhibition Venue III
Pre-function Area
Coffee Beak
Exhibition Venue II
Registration Desk
18
Sheraton Hong Kong Hotel, 4th Floor
Ming Room - FAMILY PHYSICIAN SYMPOSIUM
13:00  FP Symposium Registration here
Lunch Venue - Ching Room and Sung Room
Registration
Desk
19
SCIENTIFIC PROGRAM
08:50 – 17:00
PLENARY SESSION - BALLROOM C, 3/F
08:50 – 09:00
09:00 – 09:30
09:30 – 10:00
10:00 – 10:30
10:30 – 11:25
11:25 – 12:20
12:20 – 13:45
13:45 - 14:40
14:40 - 15:35
15:35 – 16:15
Welcome Address
UAA Lecture
"Prostate Cancer in Taiwan"
Professor TTL WU
State-of-the-Art Lecture
“Men’s Health in Asia: The Role of
Urologist”
Dato’ Professor HM TAN
Tea Break / Trade Exhibits
Oral (Free Paper) Session I
Prostate Cancer: Diagnosis to
Treatment
Oral (Free Paper) Session II
Lower Tract : Cancer and Dysfunction
Dr PSK CHU, President
Moderator
Dr BTH WONG
Moderator
Dr PC TAM
Moderators
Dr C SO, Dr TF YIU
Moderator
Dr KM LAM , Dr SK LI
Lunch / Trade Exhibits
Oral (Free Paper) Session III
BPH and Dialysis Surgery
Oral (Free Paper) Session IV
Andrology, Men’s Health and Stone
Disease
Tea Break / Trade Exhibits
Moderators
Dr WH SUN, Dr YP YUNG
Moderators
Dr FK CHEUNG, Dr PS SZETO
16:15 - 16:45
Keynote Lecture
“Testosterone Replacement Therapy in
Asian Men”
Dato’ Professor HM TAN
16:45 – 16:55
Best Paper Awards Presentation and Lucky Draw
16:55 – 17:00
Closing Remarks
Moderator
Dr SK MAK
Dr PSK CHU, President
20
SCIENTIFIC PROGRAM (Cont.)
09:00 – 15:30
CONCURRENT SESSION - TANG ROOM I, 3/F
09:00 – 10:00
Posters Viewing / Trade Exhibits (Tang Room II)
10:00 – 10:30
Tea Break / Trade Exhibits
10:30 – 11:05
11:05 – 11:33
11:33 – 13:45
Moderated Poster (Free Paper)
Session I
Prostate : Benign and Malignant
Moderated Poster (Free Paper)
Session II
Upper Tract and Robotic Surgery
Moderators
Dr FCW LEE, Dr PL LIU
Moderators
Dr SM CHU, Dr IC LAW
Poster Viewing / Trade Exhibits (Tang Room II)
HKUA UROLOGY NURSING CHAPTER
NURSING SYMPOSIUM I
Moderators
Ms. I H FONG / Ms. SN LEUNG
" Erectile Dysfunction”
Dr SK MAK
"The Nursing System & Urology Service in Macau"
14:30 – 15:00
Ms. EKW CHAN
N U R S I N G S Y MP OS I U M I I
Moderators
Ms. MN LEUNG / Ms. P SI
- F re e P ap e r S e ssi on
“Randomized Prospective Control Trial of Rectal Administration of
Xylocaine Gel and Tolerance of Transrectal Ultrasound-guided
15:00 – 15:15
Biopsy of Prostate”
Ms. WY YUNG
“Study on Using a Novel Physical Antimicrobial Dressing (JUC) on
15:15 – 15:30
Prevention of Catheter Associated Urinary Tract Infection (CAUTI)”
Mr. A IP
13:45 – 14:30
21
FAMILY PHYSICIAN SYMPOSIUM PROGRAM
13:30 – 17:00
CONCURRENT SESSION - MING ROOM II, 4/F
SESSION I
13:30 – 14:00
14:00 – 14:30
14:30 – 15:00
15:00 – 15:30
SESSION II
15:30 – 16:00
16:00 – 16:30
16:30 – 17:00
Moderators
Dr CHAN Kwok Keung Sammy / Dr LEUNG Yiu Lam Simon
“Benign Prostatic Hyperplasia”
Dr CHEUNG Man Chiu
"Overactive Bladder "
Dr WONG Kwok Tin Martin
"Erectile Dysfunction "
Dr TAM Po Chor
Tea Break / Trade Exhibits
Moderators
Dr LO Hak Keung / Dr WONG Bok Wai Byron
“Kidney Cancer”
Prof YIP Kam Hung Sidney
"Bladder Cancer "
Dr CHAN Wai Hee Steve
“Prostate Cancer "
Dr LO Kwong Yin Richard
22
ORAL (FREE PAPER) SESSION I
Prostate Cancer: Diagnosis to Treatment
10:15 – 11:25
10:30  10:41
[OP.1-1]
A Systematic Review and Meta-Analysis Comparing Three Methods
of Anesthesia for Transrectal Ultrasound Guided Prostate Biopsy
LG Liu, Q Wei, YC Zhu, X Wei, S Zheng, HC Yuan, P Han
Department of Urology
West China Hospital, Sichuan
10:41  10:52
[OP.1-2]
Prevalence of Antibiotic-Resistant Intestinal Flora in Patients
Undergoing Transrectal Ultrasonography-Guided Prostate Biopsy
(TRUS-Bx) and Its Implication for Clinical Practice: Preliminary
Results
HL Tsu1, WK Ma2, SH Lam3, KW Chan1, KC To2, WK To3, TK Ng3, PL Liu1, MK
Yiu2
Division of Urology, Department of Surgery
1
Caritas Medical Centre, 2Princess Margaret Hospital, Hong Kong
3
Department of Pathology, Princess Margaret Hospital, Hong Kong
10:52  11:03
[OP.1-3]
Association of Atypical Small Acinar Proliferation (ASAP) on
Prostate Needle Biopsy and Subsequent Prostate Cancer in Chinese
Population
HM Tam, KL Chui, SM Mak*, HY Cheung, SM Hou
Division of Urology, Department of Surgery
*
Department of Pathology
North District Hospital, Hong Kong
23
Prostate Cancer: Diagnosis to Treatment (Cont.)
11:0 3  11:14
[OP.1-4]
Survival Outcomes of Carcinoma of Prostate After Bilateral
Orchidectomy
YCJ Teoh, PKF Chiu, HY Cheung*, SM Hou, SKH Yip, CF Ng
Division of Urology, Department of Surgery
Prince of Wales Hospital, *North District Hospital, Hong Kong
11:14  11:25
[OP.1-5]
Prospective Trial of A Herbal Formula in Patients with Castration
Refractory Prostate Cancer
HC Chan, A Wong, PC Leung*, CW Cheng, CF Ng
Division of Urology, Department of Surgery
Prince of Wales Hospital, Hong Kong
*
Institute of Chinese Medicine
The Chinese University of Hong Kong, Hong Kong
24
ORAL (FREE PAPER) SESSION II
Lower Tract: Cancer and Dysfunction
11:25 – 12:20
11:25 – 11:36
[OP.2-1]
Does Second-Look TURBT Affect Management?
PKF Chiu, TY Chan, WH Au, SWH Chan
Division of Urology, Department of Surgery
Queen Elizabeth Hospital, Hong Kong
11:36 – 11:47
[OP.2-2]
Pelvic Lymph Node Dissection in Laparoscopic Radical Cystectomy
WH Au, TY Chan, HY Ngai, LY Ho, SWH Chan
Division of Urology, Department of Surgery
Queen Elizabeth Hospital, Hong Kong
11:47 – 11:58
[OP.2-3]
Transobturator Adjustable Tape Operation for Female Stress
Urinary Incontinence: Initial Experience In Tuen Mun Hospital
MC Law, C Yu, PSK Chu, CW Man
Division of Urology, Department of Surgery
Tuen Mun Hospital, Hong Kong
25
Lower Tract: Cancer and Dysfunction (Cont.)
11:58 – 12:09
[OP.2-4]
Adjustable Transobturator Male System (ATOMS) for Male PostProstatectomy Stress Urinary Incontinence: Initial Experience in
Hong Kong
MC Law#, SK Chu#, CW Man#, SY Chan*, HY Cheung+, SM Hou*
Division of Urology, Department of Surgery
#
Tuen Mun Hospital, *Prince of Wales Hospital &
+
North District Hospital, Hong Kong
12:09 – 12:20
[OP.2-5]
Extracorporeal Shock Wave Therapy for Chronic Pelvic Pain
Syndrome : The PYNEH Experience
ESK Li, CK Tai, KL Lui, KF Chau, YC Lam, CM Li, TC Fung, CW Fan
Division of Urology, Department of Surgery
Pamela Youde Nethersole Eastern Hospital, Hong Kong
26
ORAL (FREE PAPER) SESSION III
BPH and Dialysis Surgery
13:45 – 14:40
13:45 – 13:56
[OP.3-1]
Comparison of Complications of Photoselective Vaporization of The
Prostate (PVP) – Does Size of The Prostate Matter?
CC Ngo, C Yu, SK Chu, CW Man
Division of Urology, Department of Surgery
Tuen Mun Hospital, Hong Kong
13:56  14:07
[OP.3-2]
Study on Efficacy of Photoselective Vaporization of Prostate (PVP) in
Patients With Prostate <50cc or >80cc and PSA trend Postoperatively
Y Chiu, KL Chui
Division of Urology, Department of Surgery
North District Hospital, Hong Kong
14:07 – 14:18
[OP.3-3]
Does Asymptomatic Bacteriuria Increase The Risk of Post-operative
Sepsis in Transurethral Resection of Prostate (TURP) Patients?
HC Chan, H Chau, TL Ng, Y Lam, LP Si, WY Tam, WB Wong, KM Lam, HS So
Division of Urology, Department of Surgery,
United Christian Hospital, Hong Kong
27
BPH and Dialysis Surgery (Cont.)
14:18 – 14:29
[OP.3-4]
®
Prospective Cohort Study On Prostate Stent (Memokath ) in
Relieving Bladder Outlet Obstruction in Patients Who Are Too Frail
To Undergo Spinal or General Anesthesia
TK Lo, JCM Li, CW Fan
Division of Urology, Department of Surgery
Pamela Youde Nethersole Eastern Hospital, Hong Kong
14:29 – 14:40
[OP.3-5]
Arteriovenous Grafts For Hemodialysis: A Retrospective Study from A
Local Urological Centre
CH Ip, TY Chu, KC To, MK Yiu
Division of Urology, Department of Surgery
Princess Margaret Hospital, Hong Kong
28
ORAL (FREE PAPER) SESSION IV
Andrology, Men’s Health and Stone Disease
14:40 – 15:35
14:40 – 14:51
[OP.4-1]
Prospective Study on The Changes in Penile Length After
Laparoscopic Radical Prostatectomy in Chinese Men: Preliminary
Outcomes
HY Ngai, LY Ho, WH Au, SWH Chan
Division of Urology, Department of Surgery
Queen Elizabeth Hospital, Hong Kong
14:51 – 15:02
[OP.4-2]
Metabolic Syndrome in Chinese Patients with Erectile Dysfunction
HY Ngai, WH Au, SWH Chan
Division of Urology, Department of Surgery
Queen Elizabeth Hospital, Hong Kong
15:02 – 15:13
[OP.4-3]
A Comparison of The Prevalence of Cardiovascular Disease in Male
LUTS Patients With or Without Erectile Dysfunction
CY Lo, WM Lee, SM Hou, SKH Yip, CF Ng
Division of Urology, Department of Surgery,
Prince of Wales Hospital, Hong Kong
29
Andrology, Men’s Health and Stone Disease (Cont.)
15:13 – 15:24
[OP.4-4]
The Relationship between Renal Stone Excursion Distance and Body
Build during ESWL
CF Tsang, SL Ng, MH Cheung, Y Chiu, KF Fu, KL Ho
Division of Urology, Department of Surgery
Queen Mary Hospital, Hong Kong
15:24 – 15:35
[OP.4-5]
PCNL Trajectory: A Novel Concept to Predict Success in Supine
PCNL
ATL Ng, KKF Fu, KL Ho
Division of Urology, Department of Surgery
Queen Mary Hospital, Hong Kong
30
MODERATED POSTER (FREE PAPER) SESSION I
Prostate : Benign and Malignant
10:30 – 11:05
10:30  10:37
[MP.1-1]
Pattern of Use of Serum Prostate-Specific Antigen (PSA) Among NonUrologic Clinical Specialties: Retrospective Study in A District General
Hospital
HM Tam, HL Tsu, MP Yiu*, PL Liu
Division of Urology, Department of Surgery
Caritas Medical Centre, Hong Kong
*
Department of Family Medicine, Kowloon West Cluster, Hong Kong
10:37  10:44
[MP.1-2]
Thulium Laser Transurethral Prostatectomy – Early Experience From
Tuen Mun Hospital
YK Lee, PSK Chu, CW Man
Division of Urology, Department of Surgery
Tuen Mun Hospital, Hong Kong
10:44  10:51
[MP.1-3]
Single Center Experience of Prostatic Reduction Therapy with HighIntensity Focused Ultrasound for Benign Prostatic Hyperplasia
ACF Ng, HT Lok, EHY Hung*, PHT Tam*, ESY Chan, AT Ahuja*, SKH YIP
Division of Urology, Department of Surgery
*
Department of Diagnostic Radiology & Organ Imaging
Prince of Wales Hospital, Hong Kong
31
Prostate : Benign and Malignant (Cont.)
10:51  10:58
[MP.1-4]
Outcome of Patients with Benign Prostatic Hyperplasia Undergoing
Bipolar Transurethral Resection and Electrical Vaporization of
Prostate (TURP and TUEVP)
VHW Yeung, CLH Leung, RWH Chu, LS Leung, IC Law
Division of Urology, Department of Surgery
Kwong Wah Hospital, Hong Kong
10:58  11:05
[MP.1-5]
A Local Survey on Skeletal Related Complications in Patients with
Carcinoma of Prostate Having Hormonal Therapy
KW Wong, CW Wong, SC Chiang, CF Tsang, SK Li, Y Chiu, MH Wong, KF Fu,
KL Ho
Division of Urology, Department of Surgery
Queen Mary Hospital, Hong Kong
32
MODERATED POSTER (FREE PAPER) SESSION II
Upper Tract and Robotic Surgery
11:05 – 11:33
11:05  11:12
[MP.2-1]
Emphysematous Pyelonephritis: An Eight-Year Retrospective Review
across Four Hospitals in a Single Cluster
CK Chan1, HL Tsu2, WH Chu3, CK Kong4, IC Law3, PL Liu2, MK Yiu1
Division of Urology, Department of Surgery
1
Princess Margaret Hospital, 2Caritas Medical Centre &
3
Kwong Wah Hospital, Hong Kong
4
Department of Surgery, Yan Chai Hospital, Hong Kong
11:12  11:19
[MP.2-2]
Initial Experience of Robotic-assisted
Nephrectomy in a Single Center
Laparoscopic
Partial
B Ho, J Li, D Tai, B Fung, CW Fan
Division of Urology, Department of Surgery
Pamela Youde Nethersole Eastern Hospital, Hong Kong
11:19  11:26
[MP.2-3]
Robotic-Assisted Laparoscopic Uretero-ureterostomy in A Patient
with Right Retrocaval Ureter
KF Chau, CW Fan, TC Fung, CK Tai, CM Li, KW Li
Division of Urology, Department of Surgery
Pamela Youde Nethersole Eastern Hospital, Hong Kong
11:26  11:33
[MP.2-4]
Robot-Assisted Ureteral Reimplantation in Children with VesicoUreteral Reflux
CK Chan, WK Ma, TY Chu, KC To, MK Yiu
Division of Urology, Department of Surgery
Princess Margaret Hospital, Hong Kong
33
NURSING SYMPOSIUM II
Free Paper Session
15:00 – 15:30
15:00 – 15:15
[OP.N-1]
A Randomized Prospective Control Trial of Rectal Administration of
Xylocaine Gel and Tolerance of Transrectal Ultrasound-guided
Biopsy of Prostate
WY Yung, ML Li
Division of Urology, Department of Surgery
Prince of Wales Hospital, Hong Kong
15:15 – 15:30
[OP.N-2]
Study on Using A Novel Physical Antimicrobial Dressing (JUC) on
Prevention of Catheter Associated Urinary Tract Infection (CAUTI)
WK Ma, MK Yiu, MS Yim, WS Lai, KW Wong, NL Wat, A Ip
Division of Urology, Department of Surgery
Princess Margaret Hospital, Hong Kong
34
[OP.1-1]
A Systematic Review and Meta-Analysis Comparing Three Methods of
Anesthesia for Transrectal Ultrasound Guided Prostate Biopsy
LG Liu, Q Wei, YC Zhu, X Wei, S Zheng, HC Yuan, P Han
Department of Urology
West China Hospital, Sichuan
Objective:
To evaluate periprostatic nerve block (PNB), intrarectal topical anesthesia and PNB
combined with intrarectal topical anesthesia in the pain control during transrectal
ultrasound (TRUS) guided prostate biopsy.
Patients & Methods:
Randomized controlled trials (RCT) were identified, extracted and assessed using the
methods of the Cochrane library.
Results:
429 studies were initially identified from electronic database and manual search. 67
RCTs were assessed in the meta-analysis.
1) PNB, topical intrarectal topical anesthesia and PNB combined with intrarectal
topical anesthesia groups all had less pain during biopsy procedure than placebo
or control group.
2) Topical anesthesia significantly reduced pain during probe insertion compared
with control and placebo group.
3) PNB group had less pain after prostate biopsy than topical anesthesia group
4) PNB combined with topical anesthesia significantly reduced pain during biopsy
procedure compared with both PNB and topical anesthesia groups.
5) No statistically significant difference was found in adverse or serious events for
three anesthesia methods when compared to placebo and control group.
Conclusions:
1) PNB, intrarectal topical anesthesia and PNB combined with intrarectal topical
anesthesia were efficacious and safe for patients undergoing TRUS guided
prostate biopsy.
2) Topical anesthesia could significantly reduce pain during probe insertion.
3) PNB was more effective in reducing pain after biopsy procedure than topical
anesthesia.
4) PNB combined with topical anesthesia was the most effective method in
reducing pain after prostate biopsy.
35
[OP.1-2]
Prevalence of Antibiotic-Resistant Intestinal Flora in Patients
Undergoing Transrectal Ultrasonography-Guided Prostate Biopsy
(TRUS-Bx) and Its Implication for Clinical Practice: Preliminary Results
HL Tsu1, WK Ma2, SH Lam3, KW Chan1, KC To2, WK To3, TK Ng3, PL Liu1, MK
Yiu2
Division of Urology, Department of Surgery
1
Caritas Medical Centre, 2Princess Margaret Hospital, Hong Kong
3
Department of Pathology, Princess Margaret Hospital, Hong Kong
Objective :
An important factor determining the choice of antibiotic for TRUS-Bx prophylaxis and
treatment of post-biopsy infection is the prevalence of quinolone-resistant and ESBLproducing organisms in the rectum of patients undergoing this procedure. We aim to
determine these prevalence values in patients undergoing TRUS-Bx and to study their
correlation with the microbiological data of patients with post-biopsy sepsis.
Patients & Methods:
From August 2011, rectal swabs were taken from patients undergoing TRUS-Bx in
CMC and PMH before being given ciprofloxacin prophylaxis. Swabs were processed
in selective media for ciprofloxacin-resistant and ESBL-producing organisms. Patients
were prospectively studied for post-biopsy complications.
Results:
Of the 40 patients who had rectal swabs taken, 16(40%) and 17(42.5%) harbored
ciprofloxacin-resistant and ESBL-producing coliforms respectively whilst ICBLproducing coliform was found in one patient. A total of 32 bacterial colonies had their
antibiogram studied. Among the broad-spectrum antibiotics, amikacin, Tienam®, and
meropenem were 100% sensitive whilst sensitivity to Sulperazone® and Tazocin® both
reached 96.9%. Resistance towards Augmentin®, ciprofloxacin, gentamicin,
ceftriaxone, cefuroxime and Timentin® were 9.4%, 56.2%, 43.8%, 62.5%, 65.6%,
and 3.1% respectively.
Conclusions:
A relatively high prevalence of ciprofloxacin-resistant and ESBL-producing coliforms
was found in our TRUS-Bx patients, as compared to overseas data (10-22%). To our
knowledge, this is the first study on antibiotic resistance in rectal flora of Asian
patients undergoing TRUS-Bx.
36
[OP.1-3]
Association of Atypical Small Acinar Proliferation (ASAP) on Prostate
Needle Biopsy and Subsequent Prostate Cancer in Chinese Population
HM Tam, KL Chui, SM Mak*, HY Cheung, SM Hou
Division of Urology, Department of Surgery
*
Department of Pathology
North District Hospital, Hong Kong
Objective:
ASAP on initial prostate needle biopsy has been described as a predictor of
malignancy, warranting a subsequent biopsy. Our aim is to review the incidence of
ASAP and its predictive value for prostate cancer in Chinese population.
Patients & Methods:
From January 2002 to March 2011, 2301 men with suspected prostate cancer
underwent transrectal ultrasound guided prostate needle biopsy in North District
Hospital. 80 (3.5%) patients were diagnosed to have ASAP. 41 (50%) of them had
repeated biopsy. The age, DRE finding, initial PSA, PSA density (PSAD), PSA
velocity (PSAV), total prostate volume (TPV), and the pathology of the re-biopsy
specimen of these 41 patients were analyzed retrospectively.
Results:
The mean age was 67.5 (range 46-85) years. 13 (32.5%) patients were ultimately
diagnosed to have prostate cancer on subsequent biopsy. The mean time to diagnosis
of cancer on re-biopsy was 24 months, with a detection rate of 69.2% (9/13), 23.1%
(3/13), 0% (0/13), and 7.7% (1/13) at the first, second, third, and fourth re-biopsy.
Among these 13 patients, all had ipsilateral cancer involvement as the ASAP, while 6
(46.2%) had contralateral disease as well. Prostate cancer was identified at the same
site as ASAP on previous biopsy in 53.8% (7/13). Age, initial PSA, abnormal DRE,
TPV, PSAD, PSAV were not significantly different between the cancer and noncancer group. These factors were also not predictive of prostate cancer on re-biopsy
from multivariate analysis.
Conclusions:
Prostate cancer was diagnosed on subsequent biopsy in about 1/3 patients with ASAP
in Chinese population. Follow-up needle biopsy is strongly advised after initial
diagnosis of ASAP. No predictive factor of prostate cancer in ASAP patients was
identified in the current study.
37
[OP.1-4]
Survival Outcomes
Orchidectomy
of
Carcinoma
of
Prostate
After Bilateral
YCJ Teoh, PKF Chiu, HY Cheung*, SM Hou, SKH Yip, CF Ng
Division of Urology, Department of Surgery
Prince of Wales Hospital, *North District Hospital, Hong Kong
Objective:
To evaluate the overall survival outcomes in patients with carcinoma of prostate after
bilateral orchidectomy.
Patients & Methods:
Patients with carcinoma of prostate and bilateral orchidectomy performed in Alice Ho
Miu Ling Nethersole Hospital, North District Hospital and Prince of Wales Hospital
from year 2000 to 2009 were evaluated. The overall survival and subgroup analyses of
these patients were evaluated by Kaplan-Meier method.
Results:
From year 2000 to 2009, a total of 366 patients were included. The median follow up
time was 39 months. The mean age at the time of orchidectomy was 75.5 + 7.6 years.
The overall median survival was 52 months. The overall 5-year survival rate and the
cancer-specific 5-year survival rate were 45% and 54% respectively. Subgroup
analysis of median survival for patients with clinical T stages 1 to 4 were 74 months,
52 months, 52 months and 39 months respectively (p = 0.367). Subgroup analysis of
median survival for Gleason score 2-6, 7 and 8-10 were 84 months, 88 months and 45
months respectively (p = 0.009). Higher pre-orchidectomy PSA level (p = 0.043) and
higher PSA nadir (p < 0.001) were associated with poorer survival outcomes. Shorter
time to earliest PSA nadir (p < 0.001) and shorter period of PSA nadir (p = 0.019)
were associated with poorer survival outcomes. Presence of bone metastasis at the
time of orchidectomy is a predictor of poor survival outcome (p < 0.001). TURP
performed in addition to bilateral orchidectomy did not confer any survival benefit.
Conclusions:
Higher clinical T stage, higher Gleason score, higher pre-orchidectomy PSA level,
higher PSA nadir, shorter time to earliest PSA nadir, shorter period of PSA nadir and
presence of bone metastasis were associated with poorer survival outcomes in selected
patients with carcinoma of prostate undergoing bilateral orchidectomy.
38
[OP.1-5]
Prospective Trial of A Herbal Formula in Patients with Castration
Refractory Prostate Cancer
HC Chan, A Wong, PC Leung*, CW Cheng, CF Ng
Division of Urology, Department of Surgery
Prince of Wales Hospital, Hong Kong
*
Institute of Chinese Medicine
The Chinese University of Hong Kong, Hong Kong
Objective:
To assess the efficacy and safety profile of a herbal formulation in the management
of castration refractory prostate cancer
Patients & Methods:
Male patient with histological proven prostate cancer and clinically defined as in the
castration refractory stage were recruited for study. After informed consent was
obtained, they would receive a herbal formulation daily consisting of Herba
Hedyoitis diffusae (白花蛇舌草), Semen Coicis (薏苡仁), Radix Scutellariae (黃芩
), Radix Notoginseng (三七) and saw palmetto (棕櫚子). They would then be
followed up every 4-weekly for the assessment of PSA changes and also any adverse
events related to the herbs.
Results:
During the study period, there were 10 patients recruited for the study. All patients
had reached the castration refractory stage and were chemotherapy naive. Three
patients showed a drop in serum PSA level, but not reaching 50% of the baseline.
The overall mean time for PSA progression after the herbal formulation was 11.2
weeks. For patients with drop in PSA level, the mean time for PSA progression was
16.0 weeks, compared to 9.1 weeks for those with no drop in serum PSA level. There
was no adverse event reported in the cohort.
Conclusions:
The selected herbal formulation was safe and had clinical beneficial effects in some
of the patient suffered CRPC. Further studies may be needed to confirm the clinical
role of the formulation.
39
[OP.2-1]
Does Second-Look TURBT Affect Management?
PKF Chiu, TY Chan, WH Au, SWH Chan
Division of Urology, Department of Surgery
Queen Elizabeth Hospital, Hong Kong
Objective:
To review the role of second-look TURBT in bladder cancer patients
Patients & Methods:
All patients with 2nd-look TURBT done from June 2009 to May 2011 were reviewed.
Information including previous history and operation for urothelial carcinoma, indication
for TURBT, pathologies of both TURBTs, the management after 2nd-look TURBT, any
intravesical therapy and tumor recurrence were reviewed.
Results:
Among 308 TURBTs done in the above period, 37 patients had second-look TURBT done.
The patients’ mean age was 74.9 and the majority (81%) was male. The indications of 2ndlook TURBT were macroscopic residual disease after first TURBT (24.3%), tumor seen in
tumor base (48.6%), no muscle included (62.2%), T1 (67.6%), and high grade disease
(70.3%).
Patients with T1 and/or high grade with complete resection in first TURBT(n=29):
Pathology and Management after
T1 AND high T1 OR high
2nd-look TURBT
grade (n=20)
grade (n=9)
Upstage to T2
1 (5%)
1 (11%)
Upgrade
0 (0%)
1(11%)
New carcinoma-in-situ (CIS)
2 (10%)
0 (0%)
Muscle seen only in 2nd-look TURBT
7 (35%)
5 (56%)
Microscopic residual disease
6 (30%)
3 (33%)
Change of treatment
4 (20%)
2 (22%)
- Radical Cystectomy
2 (10%)
1 (11%)
- Radiotherapy
1 (5%)
1 (11%)
- BCG (for T1G3 + new CIS)
1 (5%)
0 (0%)
2nd-look TURBT useful (proper staging 10 (50%)
6 (67%)
and/or change management)
For macroscopic incomplete resection after first TURBT (n=7), 2nd-look TURBT achieved
complete resection in 43%. Overall, 77% (23/30) had post-operative Mitomycin C and
66% (19/29) had BCG. Early recurrence after 2nd-look TURBT was 25 % (5/20) at 6
months and 50% (7/14) at 1 year.
Conclusions:
2nd-look TURBT is essential for T1 and/or high grade bladder cancer.
40
[OP.2-2]
Pelvic Lymph Node Dissection in Laparoscopic Radical Cystectomy
WH Au, TY Chan, HY Ngai, LY Ho, SWH Chan
Division of Urology, Department of Surgery
Queen Elizabeth Hospital, Hong Kong
Objective:
To report the results of pelvic lymph node dissection in laparoscopic radical
cystectomy in our centre.
Patients & Methods:
Laparoscopic pelvic lymph node dissection was performed according to the template
proposed by Roth et al. in 2010 for patients with bladder cancer undergoing
laparoscopic radical cystectomy in our centre from May 2010. Patient demographic
data, operative data, pathology finding and post-operative complications were
recorded in a prospective database.
Results:
We performed laparoscopic pelvic lymph node dissection during laparoscopic radical
cystectomy in eleven patients (7 male and 4 female; mean age 66years, range 51 – 84
years) from May 2010 to June 2011. Mean total number of lymph nodes retrieved
was 27.4 (range 9 - 50). Three out of 11 patients turned out to have N2 disease and
the rest of the patients had N0 disease. One patient was readmitted for serous
discharge from drain wound and it resolved with conservative treatment.
Conclusions:
Laparoscopic pelvic lymph node dissection using the proposed template yielded an
adequate number of lymph node for N-staging in patients undergoing laparoscopic
radical cystectomy for bladder cancer.
41
[OP.2-3]
Transobturator Adjustable Tape Operation for Female Stress Urinary
Incontinence: Initial Experience In Tuen Mun Hospital
MC Law, C Yu, PSK Chu, CW Man
Division of Urology, Department of Surgery
Tuen Mun Hospital, Hong Kong
Objectives:
To analyze retrospectively the efficacy and safety of the novel transobturator
adjustable tape (TOA) operation for female stress urinary incontinence (SUI).
Patients and Methods:
From April 2009 to July 2011, 11 women mean aged 57 years (range 43 - 77) with
subjective and objective SUI demonstrated by video urodynamic study underwent
TOA. The operation was performed under either spinal or general anaesthesia. Four
groups of sutures were brought out in the obturator wound bilaterally and on both
sides of the vaginal wound for adjustment of the tape tension from Day 1 to Day 7
post-operatively. Uroflowmetry was performed upon removal of the adjustment
sutures.
Results:
Of the 11 patients, one suffered from paraplegia with continent Mitrofanoff stoma
constructed. 10/11 patients were diaper dependent and 8/11 had childbirth through
vaginal delivery. The operative time was 50.5 ± 13.2 mins. The mean number of pads
used before sling operation was 4.1 per day. It decreased to 0.3 pad per day after
operation. The cure rate (defined as pad-free status) was 80%. 3/11 required
tightening of tape while 1/11 required loosening. Among the 10 patients with
uroflowmetry performed after tape adjustment, the mean maximal flow rate was 19.6
ml/s (range 8.5 - 41.4). The mean voided volume was 327.3 ml (range 129 - 778) and
mean post void residual was 96.3 ml (range 0 - 231). None of the 11 patients reported
retention of urine or sling erosion. 1/11 had recurrent stress urinary incontinence
pending video urodynamic study.
Conclusion:
TOA seems promising as a surgical treatment of female SUI as it allows adjustment of
the tension of the tape repeatedly in the first week post-operatively. Longer follow up
and larger case series are required to ascertain its long term efficacy.
42
[OP.2-4]
Adjustable Transobturator Male System (ATOMS) for Male PostProstatectomy Stress Urinary Incontinence: Initial Experience in
Hong Kong
MC Law#, SK Chu#, CW Man#, SY Chan*, HY Cheung+, SM Hou*
Division of Urology, Department of Surgery
#
Tuen Mun Hospital, *Prince of Wales Hospital &
+
North District Hospital, Hong Kong
Objective:
To retrospectively evaluate the short term outcome of Adjustable Transobturator Male
System (ATOMS) for male post-prostatectomy stress urinary incontinence (SUI).
Patients & Methods:
From March 2010 to June 2011, 5 male patients mean aged 75 years (range 71-78)
underwent ATOMS for post-prostatectomy SUI. The ATOMS consists of a cushion for
supporting the bulbar urethra, connected to a port placed subcutaneously in the suprainguinal area for future cushion pressure adjustment.
Results:
All 5 patients had prostatectomy performed 4-8 years prior to the ATOMS
implantation. All had SUI which persisted despite pelvic floor rehabilitation and was
confirmed by video urodynamic study. The mean number of pads used was 3.6 (range
3-5). All underwent prior flexible cystoscopy and none had anastomotic stricture. The
mean operative time was 80 minutes (range 60-100). There was no bladder injury
intra-operatively. Three patients had incontinence completely cured without any
adjustment required and were diaper-free. One patient had mild SUI requiring 1 pad
per day but was satisfied with the condition and refused adjustment. One patient with
prior cystoscopic demonstration of large bladder diverticulum developed retention of
urine and required CISC three times per day in addition to spontaneous voluntary
voiding. He was still diaper-dependant and adjustment of cuff was performed two
weeks post-operatively. No sling erosion was observed in these patients.
Conclusions:
Our early experience demonstrated that ATOMS is efficacious in the treatment of male
SUI and has the advantage of being adjustable any time after operation. Moreover,
unlike the artificial urinary sphincter, it spares the patients the stress of having to
manipulate the device for micturition. However, longer follow-up and larger case
series are required to ascertain its long term efficacy.
43
[OP.2-5]
Extracorporeal Shock Wave Therapy for Chronic Pelvic Pain
Syndrome : The PYNEH Experience
ESK Li, CK Tai, KL Lui, KF Chau, YC Lam, CM Li, TC Fung, CW Fan
Division of Urology, Department of Surgery
Pamela Youde Nethersole Eastern Hospital, Hong Kong
Objective:
Extracorporeal shock wave therapy (ESWT) is well proven to be effective in other
specialties like orthopedics for the treatment of painful condition. With chronic pelvic
pain syndrome (CPPS) being one of the commonest urological diseases diagnosed in
outpatients, we aim to evaluate the effectiveness of ESWT for the treatment of CPPSrelated symptoms.
Patients & Methods:
Patients with CPPS for a minimum of 6 months, no signs of inflammation in urine
and seminal fluid and no clinical evidence of prostate cancer were included into the
study. Totally nine patients were selected. The patient was positioned on his back and
the therapy head was coupled on the perineum. At each session, 3000 pulses of
focused SW were applied at a frequency of 3.5Hz. The treatment was effected at an
energy level of 0.25mJ/mm2. The time between individual treatments was one week. A
total of 4 sessions over a course of four weeks was planned. Follow up was
performed after 4 weeks. Pre and post-treatment pain severity and frequency together
with IIEF-5 and IPSS were compared.
Results:
There was no significant difference in IPSS and IIEF-5 score after treatment. However
five out of nine patient (55.6%) showed significant decrease in pain severity (average
46.9% reduction) , duration (average 49.6% reduction) and frequency
Conclusions:
ESWT to the prostate region can be a safe and effective treatment for CPPS with
significant improvement in pain-related symptoms.
44
[OP.3-1]
Comparison of Complications of Photoselective Vaporization of The
Prostate (PVP) – Does Size of The Prostate Matter?
CC Ngo, C Yu, SK Chu, CW Man
Division of Urology, Department of Surgery
Tuen Mun Hospital, Hong Kong
Objective:
To investigate the outcome and complications of Photoselective Vaporization of
the Prostate (PVP) by retrospective evaluation in relation to prostate volume.
Patients & Methods:
From January 2006 to December 2010, 64 male patients, mean aged 75 years
(range 52-87) with mean ASA score 2.14, underwent PVP for: recurrent retention
of urine (23), obstructive uropathy (3), symptomatic BPH (36) or bladder stones
(5). All had prostate volume (P vol) assessed before operation by transrectal
ultrasound.
Outcome variables and complications were compared among 2 groups of patients.
Group A had P vol ≥ 60ml and group B had P vol 60ml.
Results:
Among the 64 patients, 19(29.6%) were on an anticoagulant and 15(23.4%) were
catheter-dependent. 41/64 patients belonged to group A with mean age of 67 and
mean ASA score of 2.1 while 23/64 belonged to group B with mean age of 73 and
mean ASA score of 2.3. In group A, 10 (24%) patients were on an anticoagulant
and 7(17%) were catheter-dependent before operation. In group B, 9(39%) patients
were on anticoagulant while 8(35%) were catheter dependent before operation.
The mean operating time, amount of energy applied and average length of stay were
respectively: 53 mins, 148 kJ and 2.5 days for group A; 73 mins, 259 kJ and 2.8
days for group B. None of the patients in group A suffered from post PVP bladder
neck stricture or retrograde ejaculations. However, among the 41 patients in group
B, 4(10%) had bladder neck stricture while 7(17%) had retrograde ejaculation.
Upon follow up at 1 year, none of the patients without bladder neck stricture
required any re-operation for intolerable LUTS.
Conclusions:
Our study showed that PVP is safe and effective as an alternative for TURP.
However, bladder neck stricture and retrograde ejaculation appeared to occur more
frequently for patients with prostate size less than 60 ml.
45
[OP.3-2]
Study on Efficacy of Photoselective Vaporization of Prostate (PVP) in
Patients With Prostate <50cc or >80cc and PSA trend Postoperatively
Y Chiu, KL Chui
Division of Urology, Department of Surgery
North District Hospital, Hong Kong
Objective:
To investigate the short and medium term efficacy of PVP with respect to different
prostate sizes. We also studied the natural history of PSA change after surgery in order
to understand the PSA trend post-operatively and offer guidance on the follow up of this
group of patients.
Patients & Methods:
113 patients with PVP done from 2008 to 2010 in North District Hospital were studied
retrospectively. Their baseline demographic and clinical data were collected. They
were assessed in our prostate clinic at 6 weeks, 3, 6, 12, 18 and 24 months postoperatively with flow rate and PSA. Data was processed with Microsoft Excel and
SPSS.
Results:
Two groups of patients were comparable in age. Average energy used in small and large
prostate groups is 195.3kJ and 373.5kJ respectively. In all patients, there was significant
improvement of IPSS and QOL throughout the 2-year follow-up period. The greatest
effect for both small and large prostates was noted at 9 months. For the flow rate
parameters, Qmax and voided volume improvement were more robust and sustained
throughout the 2-year period in large prostate group. For small prostates, Qmax at 2 years
was lower than pre-operative level. Residual urine analysis was contaminated by
patients with retention pre-operatively (~50%). The percentage drop of PSA postoperatively was similar in the 2 groups and the PSA nadir appeared at 9 months.
Overall, conversion rate to TURP was 4.4%.
Conclusions:
PVP is an effective procedure for benign prostatic hypertrophy with lower urinary tract
symptoms or retention of urine both in short and medium term. The effect is more
pronounced in patients with large prostate (>80cc) and both the clinical (Qmax, voided
volume) and biochemical parameters (PSA) showed sustained improvement over 2 years
of follow-up with the best result seen at around 9 months. Longer term follow-up is
warranted for further analysis.
46
[OP.3-3]
Does Asymptomatic Bacteriuria Increase The Risk of Post-operative
Sepsis in Transurethral Resection of Prostate (TURP) Patients?
HC Chan, H Chau, TL Ng, Y Lam, LP Si, WY Tam, WB Wong, KM Lam, HS So
Division of Urology, Department of Surgery,
United Christian Hospital, Hong Kong
Objective
To review the incidence of post-operative sepsis after TURP/TUBNI with preoperative asymptomatic bacteriuria in 2010
Patient and methods
Patients who underwent TURP / TUBNI from January 2010 to December 2010
were recruited and their data was retrieved from CDARS. Clinical sepsis, preoperative urine culture, post-operative urine/ blood culture if any were recorded.
Results
Sixty-six out of 278 patients had asymptomatic bacteriuria in pre-operative urine
culture. 73 organisms were cultured with E. Coli being the commonest. Other
common micro-organisms were Klebsiella Pneumoniae, Enterococcus and
Proteus spp.. 12 patients were treated with antibiotic according to the culture &
sensitivity before operation. Otherwise, patients were given antibiotic according to
culture & sensitivity on induction of anesthesia. 37 patients had sepsis and one
patient developed septic shock in post-operative period. 11/38 patients (postoperative sepsis/septic shock) had pre-operative positive urine culture. 3 patients
were treated with a course of antibiotic before operation. Out of these 3 patients,
one had the same organism yielded and the other two had different organisms.
Culture results of 8 patients were negative. Logistic regression showed that postoperative sepsis was not related to age, history of diabetes, anesthetic risk,
operative time and weight of tissue resected. Post-operative sepsis was neither
related to pre-operative sterile urine (negative pre-operative urine culture or treated
positive culture) nor asymptomatic bacteriuria (Pearson chi-square 0.69). In
subgroup analysis of patients with positive pre-operative urine culture, no
statistical difference was found in post-operative sepsis rates whether bacteriuria
was treated or not (Pearson chi-square 0.489).
Conclusions
No statistical difference is found in post-operative sepsis in patients with
asymptomatic bacteriuria undergoing TURP/TUBNI whether they received
antibiotic treatment pre-operatively or not.
47
[OP.3-4]
®
Prospective Cohort Study On Prostate Stent (Memokath ) in
Relieving Bladder Outlet Obstruction in Patients Who Are Too Frail
To Undergo Spinal or General Anesthesia
TK Lo, JCM Li, CW Fan
Division of Urology, Department of Surgery
Pamela Youde Nethersole Eastern Hospital, Hong Kong
Objective:
To assess the long term outcome of prostate stent in patients too frail for definitive
surgery.
Patients & Methods:
Frail patients with multiple medical co-morbidities or advanced age presenting with
acute retention of urine but failed trial of void without catheter using medication
®
were given the option of long term catheterization or prostate stent (Memokath )
insertion under local anesthesia. The patients’ pre-morbid conditions and medical
disease were recorded. The operative procedure and outcomes were measured.
Patients with prostate stent were followed up every six months and their long-term
outcomes were measured.
Results:
®
Seventeen Memokath stents were inserted with 16 patients being catheter-free on
follow up. Two patients had stent migration with one requiring repositioning and
the other requiring removal and reinsertion. One patient died from medical disease
with stent functioning in-situ.
Conclusions:
Prostate stent is a feasible option for frail patients who cannot undergo spinal or
general anesthesia. The procedure is relatively simple and no major complications
were encountered. Patient outcome so far has been satisfactory. Compared with long
term catheterization, patients are more satisfied with this option of managing their
urological condition.
48
[OP.3-5]
Arteriovenous Grafts For Hemodialysis: A Retrospective Study from
A Local Urological Centre
CH Ip, TY Chu, KC To, MK Yiu
Division of Urology, Department of Surgery
Princess Margaret Hospital, Hong Kong
Objective:
Arteriovenous grafts (AVGs) are indicated in hemodialysis patients who have failed
arteriovenous fistulae, unsuitable vessels or exhausted superficial veins. The aim of
this clinical audit is to evaluate the outcomes of AVG creation in a local urological
centre and to compare the results with international standards.
Patients & Methods:
Twenty-three AVGs were created in 19 patients between July 2009 and December
2010. Patients’ demographic data and AVG details were retrospectively retrieved
from electronic patient records. Primary patency, assisted primary patency and
secondary patency rates, as defined by Sidawy et al., were calculated. AVG
complications, failure reasons and salvage outcomes were also reviewed.
Results:
The mean age of the patients was 48 ± 10 years; and male-to-female ratio was
towards 1:1. Fourteen AVGs (61%) were created at upper extremity and eight
(35%) were created at lower extremity. All of them were non-autogenous grafts.
The mean follow-up period was 7.6 months. The cumulative patency rate of AVGs
at 6 months was 67.8%. Seven AVGs (30.4%) were complicated with
thrombosis/occlusion and two AVGs (8.7%) became infected. Steal syndrome and
pseudo-aneurysm were observed in one patient (4.3%) each. Only one AVG was
removed at 2 months post-operatively due to infection refractory to conservative
management. Thrombosis/occlusion contributed to the majority (62.5%) of
primary non-function of AVGs. Salvage procedures were performed for half of the
failed AVGs but no AVG was salvageable.
Conclusions:
The cumulative patency rate and the complication rate of AVGs in our urological
centre were comparable to international standards. Early detection of AVG failure
and prompt action may improve the salvage outcomes.
49
[OP.4-1]
Prospective Study on The Changes in Penile Length After
Laparoscopic Radical Prostatectomy in Chinese Men: Preliminary
Outcomes
HY Ngai, LY Ho, WH Au, SWH Chan
Division of Urology, Department of Surgery
Queen Elizabeth Hospital, Hong Kong
Objective:
Loss of penile length or penile girth is occasionally reported in patients who have
undergone radical prostatectomy (RP). Penile shortening was consistently observed in
early post-operative period in patients treated by open RP and robotic-assisted RP
from the available literature. Our study aims to evaluate the changes in penile length
and girth after conventional laparoscopic radical prostatectomy (LRP) prospectively.
Patients & Methods:
A total of 35 Chinese men undergoing LRP were enrolled in this prospective study.
Penile measurements consisted of Flaccid Penile Length (FPL), Stretched Penile
Length (SPL) and Penile Circumference (PC). Penile measurements were assessed and
recorded pre-operatively, on the day of foley removal after LRP and at 1, 3, 6, 9 and
12 months post-operatively. Baseline characteristics including 5-item International
Index of Erectile Function (IIEF-5) assessment were collected for analysis.
Results:
Mean age of the patients was 66.7 (range 55-79). 32 patients (91.4%) had clinical T1c
disease. Mean pre-operative FPL, SPL and PC were 8.59, 11.45 and 9.05 cm
respectively. Pre-operative mean IIEF-5 was 12.4. 18 patients (51.4%) had nervesparing LRP done. There was shortening of FPL by 0.66 (p=0.0004), 0.57 (p=0.008)
and 0.18 (p=0.49) cm respectively on day of foley removal, 1-month and 3-months
post-operatively. There were no statistically significant changes in SPL. PC was
significantly increased on day of foley removal by 0.55cm (p=0.009) but not at 1
month (0.16cm, p=0.32) and 3 months post-operatively (0.34cm, p=0.09). Mean IIEF5 was significantly reduced to 6.65 (p<0.00001) and 6.10 (p<0.00001) at 1 and 3
months post-operatively.
Conclusions:
Our preliminary data supported the finding of early shortening of flaccid penile length
in Chinese men after LRP. Longer follow-up would be invaluable for the evaluation of
natural course of penile length changes, the understanding of pathophysiology on
penile shortening and the potential implications on penile rehabilitation in patients
treated by RP.
50
[OP.4-2]
Metabolic Syndrome in Chinese Patients with Erectile Dysfunction
HY Ngai, WH Au, SWH Chan
Division of Urology, Department of Surgery
Queen Elizabeth Hospital, Hong Kong
Objective:
The association between Erectile Dysfunction (ED), Metabolic syndrome (MetS)
and cardiovascular disease has been recognized. Our aim is to evaluate the
prevalence of MetS in Chinese patients with ED from Hong Kong.
Patients & Methods:
This is a prospective study enrolling patients with ED, who were referred to our
Andrology clinic (as a tertiary referral center in Hong Kong) for assessment from
March 2011 to July 2011. Patient characteristics were recorded; physical
assessment and biochemical investigations were performed, and data was collected
for analysis.
Results:
Totally 60 Chinese patients with ED are included in the study. The median IIEF-5
score was 10. The mean age was 56 years (range 32 - 76). Half of the patients were
either smoker (18.3%, n=11) or ex-smoker (31.7%, n=19). Hypertension (50%,
n=30) and diabetes (33.3%, n=20) were the major underlying comorbidities. The
mean duration of ED symptoms was 34 months. Metabolic syndrome (MetS) was
defined according to the National Cholesterol Education Program Adult Treatment
Panel III (NCEP-ATPIII) criteria in 2005: hypertension, high fasting plasma
glucose, low HDL-cholesterol, hypertriglyceridaemia and waist circumference
≥90cm (redefined waist circumference for Chinese men according to World Health
Organization Western Pacific Region, International Association for the Study of
Obesity and International Obesity Task Force). The prevalence of MetS was 38.3%.
Hypertension (80%) and impaired glucose tolerance/ diabetes mellitus (51.7%)
remained the main contributing factors.
Conclusions:
This is the first study from Hong Kong to evaluate the prevalence of MetS among
Chinese patients with ED. Such a high prevalence (38.3%) of MetS in Hong Kong
is similar to figures from American and European populations with ED. The effort
in screening and managing the MetS serves as an important part of the holistic care
of patients having ED.
51
[OP.4-3]
A Comparison of The Prevalence of Cardiovascular Disease in Male
LUTS Patients With or Without Erectile Dysfunction
CY Lo, WM Lee, SM Hou, SKH Yip, CF Ng
Division of Urology, Department of Surgery,
Prince of Wales Hospital, Hong Kong
Objective:
There has been well documented evidence that male patients with lower urinary
tract symptom (LUTS) have higher prevalence of cardiovascular risk factors. We
would like to further evaluate the prevalence of these risk factors in these patients
with or without erectile dysfunction (ED).
Patients & Methods:
A retrospective review of a prospective collected database was performed. Male
patients with LUTS would routinely have screening of cardiovascular risk factor
during their initial assessment. The risk factors assessed included smoking status,
body mass index, diabetes status etc. The presence of ED would also be
documented. The information collected during this assessment formed the basis of
this study. Prevalence values of cardiovascular risk factors were compared using
chi-square test and multivariate logistic regression model.
Results:
In the period June 2007 to June 2010, 1133 patients were assessed in our clinic for
LUTS. The mean age was 64.6 (29-97) years old. There were 471 male with normal
sexual function (no-ED), 185 patients with ED and 428 patients reported no sexual life
(no-sex). When comparing ED with no-ED patients, ED patients had significantly
higher prevalence of diabetes (p=0.002), hypertension (p=0.019) and smoking
(p=0.015). When comparing no-sex patient with no-ED patients, no-sex patients had
significantly higher prevalence of diabetes (p=0.004), hypertension (p=0.003) and
smoking (p=0.001). No significant difference was found between ED and no-sex
patients. With ED and no-sex patients combined together, a significant higher
prevalence of diabetes (p=0.001), hypertension (p=0.001) and smoking (p=0.001)
was found, when compared to no-ED patients.
Conclusions:
Among male patients with LUTS, ED and no-sex patients had significantly higher
prevalence of diabetes, hypertension and smoking. Targeted cardiovascular risk
factors screening should be directed to these patients to increase the costeffectiveness.
52
[OP.4-4]
The Relationship between Renal Stone Excursion Distance and Body
Build during ESWL
CF Tsang, SL Ng, MH Cheung, Y Chiu, KF Fu, KL Ho
Division of Urology, Department of Surgery
Queen Mary Hospital, Hong Kong
Aim:
To study the relationship between body build and renal stone excursion distance
during ESWL.
Patients and Methods:
88 consecutive patients with different urinary stones underwent ESWL from Oct
2010 to Feb 2011. Patients with ureteric stone, incomplete data, double-J stent and
PCN in-situ were excluded. Stone characteristics including burden, position and
excursion at deep inspiration and expiration were recorded. Patient factors
including body height, body weight, body mass index and waist circumference were
measured. Stone and patient data collected were analyzed.
Results:
The correlation between stone excursion with BMI, body height, body weight, and
waist circumference was analyzed by Pearson correlation test. During ESWL for
renal stones, there was significant distance of excursion of renal stone (mean 20mm
± SD 11mm). The stone excursion distance was not affected by the body height,
body weight, body mass index and waist circumference.
Conclusion:
BMI, body height, body build and waist circumference do not affect the renal stone
excursion distance and theoretically these factors should not affect the stone
clearance rates. More studies are needed to study the determining factors of stone
excursion distance and to determine the relationship of stone excursion distance
with stone clearance rates. These will be studied in the second phase of this study.
53
[OP.4-5]
PCNL Trajectory: A Novel Concept to Predict Success in Supine
PCNL
ATL Ng, KKF Fu, KL Ho
Division of Urology, Department of Surgery
Queen Mary Hospital, Hong Kong
Objective:
Supine PCNL confers certain advantages over its prone counterpart but access
parameters change with supine positioning. Supine position limits maneuverability
of instruments, limiting access to upper and mid-pole stones. We aim to determine
predictive factors for success of supine PCNL through road-mapping of PCNL
trajectory.
Patients & Methods:
Patients undergoing PCNL from July 2010 to August 2011 were recruited.
Choice of position was made by surgeon. Tracts were performed under USG &
fluoroscopy. Distances and angles were measured intra-operatively with rigid and
flexible nephroscopes, and correlated with pre-operative imaging. Patients with
unconventional anatomy were excluded (duplex system / caliceal stones with
narrow infundibulum)
Results:
21 patients underwent PCNL (11 supine, 10 prone). Stone load was greater in the
prone group. Overall stone clearance after single PCNL was 71%, with mean size
of residual stone fragment 12 mm. Regardless of abdominal thickness and
approach, all lower pole and renal pelvic stones were reached with mean excursion
of 138 mm in supine & 88 mm in prone position; mean-entry angle was 60° for
supine, and 44° for prone for PUJ access. In supine PCNL, the upper pole was
reached in 3 of 11 tracts, with mean-excursion of 168 mm & entry angle of 35°.
Similarly, 2 of 11 supine PCNL reached middle pole. Conversely, all prone PCNL
tracts reached upper & middle pole with decreased excursion & angle.
Conclusion:
PCNL in prone position can reach renal pelvis and 3 poles via lower pole
puncture. PCNL trajectory may be a tool to predict success in supine PCNL by
estimating chance of reaching mid & upper pole. Skin to upper pole distance larger
than 185mm and entry angle more than 48° decrease chance of upper pole access
for supine PCNL.
54
[MP.1-1]
Pattern of Use of Serum Prostate-Specific Antigen (PSA) Among
Non-Urologic Clinical Specialties: Retrospective Study in A District
General Hospital
HM Tam, HL Tsu, MP Yiu*, PL Liu
Division of Urology, Department of Surgery
Caritas Medical Centre, Hong Kong
*
Department of Family Medicine, Kowloon West Cluster, Hong Kong
Objective:
PSA test is frequently requested by non-urologists for various reasons but there is
paucity of data of how it is being used. The prevalence of prostate cancer screening
using PSA among non-urologists is also unknown. Our aim is to review the pattern
of use of this test among non-urologists.
Patients & Methods:
Case notes of patients with PSA tests requested by non-urologic specialties in CMC
and three nearby GOPCs were retrospectively reviewed. Demographic data of the
patients, circumstances leading to the PSA test, action based on the test result and
patient outcome were studied.
Results:
From January to March 2010, 265 PSA tests were performed by non-urologic
specialties. Mean age of the patients was 68.0±12.6, with median PSA level 1.7
ng/ml (range 0.1-9424). PSA tests were done most often for workup of LUTS
(34.8%) and serial monitoring (15.5%). Only 3% of tests were done for prostate
cancer screening. No valid indication can be identified in 24.6% of tests. For the
purpose of LUTS workup and screening/monitoring, 15% of tests were done in
patients aged ≥80. PSA was tested during an episode of AUR and suspected UTI in
4.2% and 2.3% cases respectively. An adjunctive DRE was not performed in
73.1% at the time of PSA testing. Using a cut-off of 4ng/ml, no actions were taken
based on an elevated PSA after 42% of tests. At a mean follow-up of 13.8±5.3
months, 7 cases of prostate cancer were diagnosed in the entire cohort.
Conclusions:
A proportion of PSA tests were performed without clear indications or in the
presence of contraindications. There was underutilization of DRE in conjunction
with PSA tests by non-urologists. Practice of PSA testing for prostate cancer
screening appeared uncommon but a significant number of testing was devoted to
serial monitoring.
55
[MP.1-2]
Thulium Laser Transurethral Prostatectomy – Early Experience
From Tuen Mun Hospital
YK Lee, PSK Chu, CW Man
Division of Urology, Department of Surgery
Tuen Mun Hospital, Hong Kong
Objective:
Our aim is to verify the ability of the new technology and to see if any
modification to patient recruitment and post-operative care can be made.
Patients & Methods:
From 8th July to 30th Aug 2011, 9 male patients with mean age 77.3 years (range
61 - 85) underwent thulium laser prostatectomy in Tuen Mun Hospital. One
patient had history of ischaemic heart disease with angioplasty done. Clopidogrel
was stopped for 1 week before the operation. One other patient had history of
atrial fibrillation on aspirin 160mg daily. Aspirin was stopped 1 day before
operation and was resumed on post-operative day one. Some other notable comorbidities or past history among patients include chronic subdural haemorrhage
with burr-hole done, chronic renal failure and myelodysplastic syndrome.
Concomitant operation was done in 2 of the cases. One of them was right URSL
and the other was right inguinal hernia repair and resection of cord lipoma.
Results:
The average operative time for laser prostatectomy alone (7 cases) was 71
minutes. Among the 9 cases done, blood transfusion was needed in 2 cases. Two
of the cases had prolonged hospitalization due to sepsis and positive urine culture.
Apart from these 2 cases, on average, patients can be discharged on post-operative
day 3. None of the patients needed to be re-admitted after the operation from
follow up day 1 to 56.
Conclusions:
Thulium laser is a promising new technology that can benefit our patients with its
excellent haemostatic property. Hospital stay is expected to be further shortened
because post-operative bleeding is minimal and bladder irrigation can be omitted
in selected cases. More detailed research has to be done to verify its comparability
to the gold standard of TURP with regards to long term outcomes.
56
[MP.1-3]
Single Center Experience of Prostatic Reduction Therapy with HighIntensity Focused Ultrasound for Benign Prostatic Hyperplasia
ACF Ng, HT Lok, EHY Hung*, PHT Tam*, ESY Chan, AT Ahuja*, SKH YIP
Division of Urology, Department of Surgery
*
Department of Diagnostic Radiology & Organ Imaging
Prince of Wales Hospital, Hong Kong
Objective:
To evaluate the clinical effectiveness and adverse effects of High-Intensity Focused
Ultrasound (HIFU) in treating patients with BPH
Patients & Methods:
Patients with significant lower urinary tract symptoms (International Prostate
Symptom Score ≥ 8), either Foley catheter-dependent or Foley catheterindependent, were recruited in this prospective single-arm study. For Foley
catheter-independent patients, a Foley catheter was placed in the urinary bladder for
14 days before HIFU. Three sessions of HIFU were given to each patient. The
patients were followed up at 2 weeks, 2 months, 6 months and 12 months. Primary
end points were defined as ability to wean off Foley catheter for Foley catheterdependent patients and BPH symptoms, as measured by International Prostate
Symptom Score (IPSS) for Foley catheter-independent patients.
Results:
From September 2009 to June 2010, 14 patients were recruited for this study.
Among them, 6 patients were Foley catheter-dependent and 8 patients could void
with significant lower urinary tract symptoms. All of them received 3 sessions
HIFU treatment uneventfully. Upon 1 year follow-up, 2 out of 6 Foley catheterdependent patients (33%) weaned off from catheter successfully. Five out of 8
Foley catheter-independent patients had significant improvement in BPH
symptoms, evidenced by reduced IPSS and dose of alpha-blockers. One Foley
catheter-independent patient failed to wean off catheter after the procedure and
required subsequent TURP. Otherwise, no complication was reported.
Conclusions:
HIFU is a safe alternative treatment for patients with BPH with retention of urine
or significant symptoms, especially those with high surgical risk.
57
[MP.1-4]
Outcome of Patients with Benign Prostatic Hyperplasia Undergoing
Bipolar Transurethral Resection and Electrical Vaporization of
Prostate (TURP and TUEVP)
VHW Yeung, CLH Leung, RWH Chu, LS Leung, IC Law
Division of Urology, Department of Surgery
Kwong Wah Hospital, Hong Kong
Objective:
Both bipolar TURP and TUEVP are performed with normal saline, thus
minimizing TUR syndrome. By combining the usage of both the loop and the
button electrode, an effective prostate tissue clearance along with good hemostasis
can be achieved during the operation.
Patients & Methods:
115 patients who underwent a hybrid of bipolar TURP and TUEVP in our hospital
from January 2008 to July 2011 were recruited into the study. The pre-operative
patients’ medical conditions and medications, indications of operation, operation
time, blood loss, post-operative outcomes and length of hospital stay were
included in the analysis.
Results:
The average age of the patients was 73.1 years, and 27 (23.5%) of them were on
aspirin, Plavix or warfarin due to medical diseases. The average operative blood
loss was 175.5 ml, and the mean operative time was 71.8 minutes. The median
length of hospital stay was 5 days, and 105 (91.3%) patients were able to wean off
Foley upon discharge from the hospital. Subgroup analysis showed that the
outcomes of the patients with pre-operative anti-coagulants (aspirin / Plavix /
warfarin) were similar to those without these medications.
Conclusions:
The combination approach of bipolar TURP and TUEVP could achieve resection
of prostate in a safe and effective manner. Future studies should focus on those
patients who have high risks in stopping their anti-coagulants peri-operatively.
58
[MP.1-5]
A Local Survey on Skeletal Related Complications in Patients with
Carcinoma of Prostate Having Hormonal Therapy
KW Wong, CW Wong, SC Chiang, CF Tsang, SK Li, Y Chiu, MH Wong, KF Fu, KL
Ho
Division of Urology, Department of Surgery
Queen Mary Hospital, Hong Kong
Objective:
To study the skeletal related complications in patients with carcinoma of prostate
having hormonal therapy
Patients & Methods:
Patients diagnosed to have carcinoma of prostate and had either bilateral
orchidectomy or commencements of LHRH analogue injection from 1st January,
2007 to 31st December, 2009 in Queen Mary Hospital were studied. Basic
characteristics, presence of skeletal related complications and related information
were collected. Data were processed with SPSS.
Results:
A total of 106 patients were studied. 46 patients had bilateral orchidectomy done and
60 patients had LHRH analogue injection started. The skeletal related complication
rate was low. Patients with metastatic carcinoma of prostate had higher chance of
skeletal related complication rate compared with those with non-metastatic disease.
Conclusions:
Skeletal related complications cause significant impact to patients with carcinoma of
prostate. Metastatic carcinoma of prostate increases the risk of pathological fracture.
Hormonal therapy for patients with carcinoma of prostate decreases the chance of
pathological fracture but leads to osteoporosis. Patients with metastatic carcinoma of
prostate had higher chance of skeletal related complication rate compared with those
with non-metastatic disease.
59
[MP.2-1]
Emphysematous Pyelonephritis: An Eight-Year Retrospective
Review across Four Hospitals in a Single Cluster
CK Chan1, HL Tsu2, WH Chu3, CK Kong4, IC Law3, PL Liu2, MK Yiu1
Division of Urology, Department of Surgery
1
Princess Margaret Hospital, 2Caritas Medical Centre &
3
Kwong Wah Hospital, Hong Kong
4
Department of Surgery, Yan Chai Hospital, Hong Kong
Objective :
Emphysematous pyelonephritis (EPN) is a rare but life-threatening infection. We
aim to review our cluster’s experience of managing this urologic emergency.
Patients & Methods
Case notes of patients with EPN in four acute hospitals in the KWC (PMH, CMC,
KWH and YCH) were retrospectively reviewed. The patients’ demographic data,
clinical presentation, investigation findings, treatment and outcome were studied.
Results
From January 2003 to July 2011, 8 patients were diagnosed with EPN. Their
mean age was 68.4±11.7 and all except one had diabetes mellitus. Their clinical
presentation included fever (37.5%), flank pain (75%) and septic shock (37.5%).
Half of patients required immediate ICU admission. The diagnosis of EPN was
made by CT in all of the patients. Three patients had gas extension into perinephric
space (Huang & Tseng Class 3a) whilst 2 patients had abscess collection involving
contiguous organs. E. coli, Klebsiella and Proteus spp were cultured from 87.5%,
50% and 12.5% of patients respectively. Immediate nephrectomy was performed
in five patients whilst conservative treatment was adopted in three. In this latter
group, one patient required subsequent emergency nephrectomy, one recovered
and one died. Overall 4 patients survived to be discharged. Analysis of our small
cohort revealed postoperative requirement of inotropic support to be the only
factor significantly associated with adverse outcome (p=0.029).
Conclusions
EPN is a serious condition with significant mortality. The need for postoperative
inotropic support is shown to be an adverse risk factor. Further analysis involving
other local EPN patients is required for better prognostication to guide its
management.
60
[MP.2-2]
Initial Experience of Robotic-assisted Laparoscopic Partial Nephrectomy in a
Single Center
B Ho, J Li, D Tai, B Fung, CW Fan
Division of Urology, Department of Surgery
Pamela Youde Nethersole Eastern Hospital, Hong Kong
Objective:
To review a single center’s initial experience in robotic-assisted laparoscopic
partial nephrectomy and compare our results with established centers.
Patients & Methods:
Retrospective review of 11 patients who underwent robotic-assisted laparoscopic
partial nephrectomy from January 2010 to July 2011 was performed. Patient
demographics, tumor characteristics, operative parameters, post-operative
complications, and subsequent renal function were reviewed and compared to
overseas and local centers.
Results:
Mean age of patients was 56 years (range 45 to 78). Only 1 patient presented with
hematuria, the rest (10 patients) were incidentally found to have renal tumor. Mean
tumor size was 1.8cm (range 0.8 to 3.3). Patients’ mean baseline renal function
was 93.2 µmol/L (range 63 to 166) with mean eGFR of 78.3 ml/min/m2 (range
41.5 to 104.1). Ten patients underwent the operation with clamping of the renal
pedicles with a mean warm ischemia time of 26.7mins. Mean blood loss was
228ml. Mean hemoglobin drop on post-operative day 1 or 2 was 1.1g/dl (95% CI=
0.4 to 1.8). One patient had a partial nephrectomy without clamping. Mean
operative duration was 251mins. Mean hospital stay was 8.3 days (range 4 to 18).
Pathology results came back to be angiomyolipoma (4 patients), T1a renal cell
carcinoma (6 patients), and T3a renal cell carcinoma (1 patient). Only 2 patients
had a focally involved margin on pathology review. Mean eGFR deterioration was
12.1 ml/min/m2. Only 1 patient required conversion due to persistent bleeding
from nephrectomy site despite compression sutures. Two patients had significant
surgical complications (pseudoaneurysm and venous thrombosis of ipsilateral renal
vein). Our results are comparable to those from previously published overseas and
local studies.
Conclusions:
Robotic-assisted laparoscopic partial nephrectomy is safe and technically feasible,
but its long term effect on renal function remains to be investigated.
61
[MP.2-3]
Robotic-Assisted Laparoscopic Uretero-ureterostomy in A Patient
with Right Retrocaval Ureter
KF Chau, CW Fan, TC Fung, CK Tai, CM Li, KW Li
Division of Urology, Department of Surgery
Pamela Youde Nethersole Eastern Hospital, Hong Kong
Objective:
The advent of robotic surgery has embarked on revolutionary changes in the
development of Urology, where the demand for complex reconstruction, precise
vascular control and adequate organ exposure used to be major obstacle to the
minimal access approach. Herein, we describe the application of robotic-assisted
laparoscopic uretero-ureterostomy in a patient with right retrocaval ureter.
Patients & Methods:
A 56-year-old gentleman presented with right sided loin pain and impaired renal
function. Subsequent CT urogram showed right retrocaval ureter. Roboticassisted laparoscopic uretero-ureterostomy was performed using the da Vinci
Surgical System.
Results:
The procedure was successfully completed in a minimally invasive fashion with
operative time of 195 min and an intra-operative blood loss of only 20 ml. The
post-operative course was uneventful and the patient was discharged on postoperative day 6.
Conclusion:
Robotic-assisted laparoscopic uretero-ureterostomy is a safe and feasible option
in experienced hands.
62
[MP.2-4]
Robot-Assisted Ureteral Reimplantation in Children with VesicoUreteral Reflux
CK Chan, WK Ma, TY Chu, KC To, MK Yiu
Division of Urology, Department of Surgery
Princess Margaret Hospital, Hong Kong
Objective:
We report our initial experience on robot-assisted ureteral reimplantation in
children with vesico-ureteral reflux (VUR).
Patients & Methods:
Two patients with VUR were referred to our unit for management. One patient had
bilateral VUR (right grade IV and left grade II) and the other patient had right-sided
grade III reflux. Both presented with UTI and prophylactic antibiotic was started.
DMSA scan showed evidence of renal scars formation and breakthrough UTI were
documented in both cases. Therefore, robot-assisted extra-vesical ureteral
reimplantation was performed (at 16 and 25 months of age) in both patients. The
surgical technique will be discussed.
Results:
There was no open conversion or intra-operative complication. The console time
was 140 minutes for unilateral and 160 minutes for bilateral repair. Foley catheter
was removed on post-operation day 1, and both voided well and were discharged
after foley removal. Post-operative MCUG showed complete VUR resolution in all
3 ureters.
Conclusions:
Our initial results are encouraging. Robot-assisted extravesical ureteral
reimplantation is another safe and effective option for repair of VUR.
63
[OP.N-1]
A Randomized Prospective Control Trial of Rectal Administration of
Xylocaine Gel and Tolerance of Transrectal Ultrasound-guided
Biopsy of Prostate
WY Yung, ML Li
Division of Urology, Department of Surgery
Prince of Wales Hospital, Hong Kong
Objective:
To evaluate the effectiveness of rectal administration of Xylocaine gel towards
transrectal ultrasound-guided prostatic biopsies.
Method:
From August to December 2010, 120 patients undergoing transrectal ultrasoundguided biopsy were asked to score their pain tolerability using post biopsy
questionnaire with a 10 cm linear visual analogues scale (VAS).The population
was divided into 2 groups. In group 1, 15 ml of 2% Xylocaine jelly was
administrated intrarectally 5 minutes before the procedures. In group 2, 15 ml of
soluble K-Y gel was administrated under the same conditions. Both patients and
physicians were unaware of which product was used.
Conclusion:
In both groups, mild or no pain was reported by majority of patients. The average
pain score of group 1 and 2 were 4.4 and 4.1 respectively. 81.4% of patients
judged that the procedure should not be performed under general anesthesia. Even
when anesthesia-free, the procedure was felt to cause mild pain by majority of
patients. The rectal administration of Xylocaine gel has no significant impact on
their pain tolerance towards prostatic biopsy.
64
[OP.N-2]
Study on Using A Novel Physical Antimicrobial Dressing(JUC) on
Prevention of Catheter Associated Urinary Tract Infection (CAUTI)
WK Ma, MK Yiu, MS Yim, WS Lai, KW Wong, NL Wat, A Ip
Division of Urology, Department of Surgery
Princess Margaret Hospital, Hong Kong
Introduction:
Urinary tract infection (UTIs) is common and accounts for about 40% of healthcare associated infections. Majority of UTIs are associated with indwelling urinary
catheters. Catheter related UTIs have a significant impact on hospital cost. There
are many innovative strategies for prevention of catheter associated urinary tract
infection (CAUTI). A novel physical antimicrobial dressing (JUC) is a potential
product that may prevent CAUTI. To investigate the effectiveness of JUC on
prevention of CAUTI, we studied patients with retention of urine that required
urinary catheter for drainage. Before carrying out the study, we collected urine
culture from patients on urinary catheter as baseline data and monitored the
infection rate among them. A pilot study on the effectiveness of JUC on prevention
of urinary catheter associated infection was carried out.
Method:
Patients admitted for retention of urine were recruited. Urine culture was saved
before insertion of urinary catheter. Patients were admitted for trial of wean off
catheter 2 weeks later. Urine culture was saved again before catheter was taken off.
Another group of patients with retention of urine was recruited as control group.
Urine culture was also saved before weaning off catheter.
Results:
In the period between 2/2010 and 4/2011, totally 30 cases were recruited as
baseline study data. Over 70% of patients had increase in bacterial counts and
developed urinary tract infection after insertion of foley for 2 weeks. The control
group had similar condition.
Conclusion:
Urinary catheter insertion has a significant impact on patients. Evidence showed
that bacteriuria and urinary tract infection occurred after foley insertion for 2
weeks. Further double-blinded randomized controlled study is needed to establish
the efficacy of the study.
65
EXHIBITION FLOOR PLAN
SD1) Karl Storz Endoscopy China Ltd.
SD2) Olympus Hong Kong & China Ltd.
D1)
D2)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
Pfizer Corporation HK Ltd.
Novartis Pharmaceutical (HK) Ltd.
Associated Medical Supplies Co Ltd
Tronda Electronics Ltd.
Cook Medical
Esaote China Ltd.
Ipsen Pharma Hong Kong
Tristel Asia Ltd.
Ferring Pharmaceuticals Ltd.
Astellas Pharma HK Co Ltd.
Bayer Healthcare Ltd.
Sino Spirit Medical Ltd.
Medical Distributor Alliance Ltd.
Lumenis (HK) Ltd.
Newtech International Trading Ltd.
Synmosa Biopharma (HK) Co. Ltd.
L F Asia (HK) Ltd.
Beckman Coulter Hong Kong Ltd.
Johnson & Johnson (HK) Ltd.
sanofi-aventis Hong Kong Ltd.
Takeda Pharmaceuticals (Taiwan) Ltd.
- Hong Kong Branch
Jacobson Medical (HK) Ltd.
GlaxoSmithKline Ltd
Eli Lilly Asia Inc.
Humane Link Ltd.
Caster (HK) Medical Supplies Co. Ltd.
Shun On Healthcare Ltd.
66
SPONSOR PROFILE
Abbott International Hong Kong
20/F, AIA Tower
183 Electric Road
North Point, HONG KONG
Website: www.abbott.com.hk
Booth 1
Associated Medical Supplies Co Ltd.
Room 1201, Fo Tan Industrial Centre
26 Au Pui Wan Street, Fo Tan
New Territories, HONG KONG
Website: www.amscl.com
Email: [email protected]
Booth 8
Astellas Pharma Hong Kong Co. Ltd.
Unit 1103-07, 11/F, Tower 1
Grand Century Place
193 Prince Edward Road West
Mongkok, Kowloon, HONG KONG
Website: www.astellas.com.hk
Booth 9
Bayer HealthCare Limited
803-808, 8/F, Shui On Centre
6-8 Harbour Road
Wanchai, HONG KONG
Website: www.bayerscheringpharma.de
Booth 16
Beckman Coulter Hong Kong Ltd.
12th Floor, Oxford House
979 King’s Road
Taikoo Plaza, HONG KONG
Website: www.beckmancoulter.com
Booth 24
Caster (HK) Medical Supplies Ltd.
Room 606, Chevalier Commercial Centre,
8 Wang Hoi Road,
Kowloon Bay, Hong Kong
Website: [email protected]
67
Mr. Harry Tsui
Senior Product Manager
Primary Care
Tel: (852) 2806 4870
Mobile (852) 9035 7864
Email: [email protected]
Ms. Ivy T. W. Chan
Marketing Specialist
Tel: (852) 2604 9389
Email: [email protected]
Ms. Rachel KWAN
Product Manager - Urology
Tel: (852) 2377 9801
Email: [email protected]
Mr. Raymond CHAN
Senior Group Product Manager General Medicine
Tel: (852) 8200 2034
Email: [email protected]
Ms. Peggy Lam
Department Administrator
Tel: (852) 2240 6203
Email: [email protected]
Mr. Andrew WU
General Manager
Tel: (852) 2755 8200
SPONSOR PROFILE (Cont.)
Booth 3
Cook Medical
Unit 1101-03, 11/F, Tai Tung Building
8 Fleming Road
Wan Chai, HONG KONG
Website: www.cookmedical.com
Ms. Avis CHAN
Territory Sales Manager
Tel: (852) 93055315
Email: [email protected]
Booth 22
Eli Lilly Asia, Inc.
Suites 2501-9, Shell Tower, Time Square
1 Matheson Street
Causeway Bay, HONG KONG
Website: www.lilly.com.hk
Ms. Nissa YUEN
Business Associate
Tel: (852) 9083 0776
Email: [email protected]
Booth 4
Esaote China Ltd.
18/F, Bonham Strand Trade Centre
135 Bonham Strand
Sheung Wan, HONG KONG
Website: www.esaote.com
Mr. Kinson NG
Sales Supervisor
Tel: (852) 6274-7257
Email: [email protected]
Booth 7
Ferring Pharmaceuticals Ltd.
Unit 1-12, 25th Floor
1 Hung To Road, Ngau Tau Kok
Kowloon, HONG KONG
Website: www.ferring.com.hk
Mr. Lawrence WONG
Product Manager-HK & SEA Region
Tel: (852) 2622 8181
Email: [email protected]
Booth 21
GlaxoSmithKline Ltd.
23/F, Tower 6, The Gateway
9 Canton Road, Tsim Sha Tsui
Kowloon, HONG KONG
Website: www.gsk.com.hk
Mr. Henry LEUNG
Product Manager
Tel: (852) 3189 8989
Email: [email protected]/
Booth 23
Humane Link Limited
Unit 827, 8/F, Ocean Centre
Harbour City, 5 Canton Road
Tsim Sha Tsui, Kowloon, HONG KONG
Email: [email protected]
Ms. Marilyn NG
Business Development Manager
Mr. Anson Lai
Sales & Service Engineer
Tel: (852) 5489-3397
68
SPONSOR PROFILE (Cont.)
Booth 5
Ipsen Pharma Hong Kong
13/F, Lifung Centre
2 On Ping Street, Siu Lek Yuen
Shatin, New Territories, HONG KONG
Website: www.ipsen.com
Booth 20
Jacobson Medical (Hong Kong) Ltd.
15/F, China Trade Centre
122-124 Wai Yip Street, Kwun Tong
Kowloon, HONG KONG
Website: www.jacobsonmedical.com.hk
Email: [email protected]
Ms. Samantha AU YEUNG
Product Executive
Tel: (852) 9194 0564
Email: [email protected]
Mr. Ringo WONG
Marketing Director
Tel: (852) 2199 5610
Email: [email protected]
Booth 17
Johnson & Johnson (HK) Ltd.
Room 1001-9, 10/F, Tower 2
Grand Century Place
193, Prince Edward Road West
Mongkok, Kowloon, HONG KONG
Mr. Victor YU
Product Specialist
Tel: (852) 6409 0036
Email: [email protected]
Booth SD1
Karl Storz Endoscopy China Ltd.
Unit 1601, Chinachem Exchange Square
1 Hoi Wan Street
Quarry Bay, HONG KONG
Website: www.karlstorz.com
Mr. Cyrus KWOK
Marketing Executive
Tel: (852) 2865 2411
Email: [email protected]
Booth 15
LF Asia (HK) Ltd.
15/F, LiFung Centre
2 On Ping Street, Siu Lek Yuen
Shatin, New Territories, HONG KONG
Booth 12
Lumenis (HK) Ltd.
Unit 2602, 26/F, Miramar Tower
132 Nathan Road, Tsim Sha Shui
Kowloon HONG KONG
Website: www. Lumenis.com
69
Ms. Josephine KWAN
Assistant Manager
Tel: (852) 2635 5840
Email: [email protected]
Mr. Eddie NG
Regional Marketing Manager
Tel: (852) 21742800
Email: [email protected]
SPONSOR PROFILE (Cont.)
Booth 11
Medical Distributor Alliance Ltd.
Unit 1301, Charmay Centre
12 Ka Hing Road, Kwai Chung
New Territories, HONG KONG
Website: www.mdaco.com
Email: [email protected]
Mr. Adrian ZHANG
Managing Director
Tel: (852) 35905130
Mobile: (852) 9371 3733
Email: [email protected]
Booth 13
NewTech International Trading Ltd.
Room 1903, Winning Centre
29 Tai Yau Street, San Po Kong
Kowloon, HONG KONG
Website: [email protected]
Mr. Danny LEUNG
Sales Manager
Tel: (852) 2323 3018
Mobile: (852) 9682 8655
Email: [email protected]
Booth D2
Novartis Pharmaceutical (HK) Ltd.
27/F, Fortis Centre
1063 King's Road
Quarry Bay, HONG KONG
Website: www.novartis.com.hk
Mr. Alan NG
Product Manager
Tel: (852) 2882 4288
Mobile: (852) 8203 3262
[email protected]
Booth SD2
Olympus Hong Kong and China Ltd.
L43 Office Tower, Langham Place
8 Argyle Street, Mongkok
Kowloon, HONG KONG
Website: www.olympus.com.hk
Booth D1
Pfizer Corporation Hong Kong Ltd.
16/F, Stanhope House
738 King’s Road
North Point, HONG KONG
Website: www.pfizer.com.hk
Booth 18
sanofi-aventis Hong Kong Ltd.
25/F, Windsor House
311 Gloucester Road
Causeway Bay, HONG KONG
Website: www.sanofi.hk
Mr. Kelvin LAI
Marketing Manager
Tel: (852) 2170 5682
Email: [email protected]
Mr. Gary CHEUNG
Senior Product Manager
Tel: (852) 6621 2299
Mobile: (852) 9728 6857
Email: [email protected]
Mr. Raymond LEUNG
Assistant Product Manager, Taxotere
Tel: (852) 9866 4934
70
SPONSOR PROFILE (Cont.)
Booth 25
Shun On Healthcare Limited
Room3101-09, 31/F, Standard Chartered Tower
Millennium City One, 388 Kwun Tong Road
Kowloon, HONG KONG
Website: www.sohealthcare.com
Ms. Winnie LAM
Sales and Marketing Manager
Tel: (852) 3123 8060
Mobile: (852) 9852 9794
Email: [email protected]
Booth 10
Sino Spirit International Ltd.
Unit 1806, Cheung Tat Centre
18 Cheung Lee Street
Chai Wan, HONG KONG
Mr. Edison CHUNG
Director
Tel: (852) 2515 1802
Email: [email protected]
Booth 14
Synmosa Biopharma (HK) Co. Ltd.
Flat F, 9/F, Hop Hing Industrial Building
702-704 Castle Peak Road, Lai Chi Kok
Kowloon, HONG KONG
Website: www.synmosa.com.tw
Booth 19
Takeda Pharmaceuticals Taiwan Ltd.
– Hong Kong Branch
Unit 2301A, 23rd Floor
Bank of East Asia Harbour View Centre
56 Gloucester Road
Wan Chai, HONG KONG
Website: www.takeda.com
Booth 6
Tristel Asia Ltd.
1802, Worldwide House
19 Des Voeux Road
Central, HONG KONG
Website: www.tristel.com
Email: [email protected]
Booth 2
Tronda Electronics Ltd.
Suite 601-602, 6/F Lever Tech Centre
69-71 King Yip Street, Kwun Tong
Kowloon, HONG KONG
71
Mr. Leon POON
Sales Supervisor
Tel: (852) 2708 9166
Email: [email protected]
Mr. Ho KWOK
Key Account Manager
Tel: (852) 2861 2218
Email: [email protected]
Ms. Lucy MORRIS
Business Manager
Tel: (852) 3667 9253
Email: [email protected]
Mr. Terence CHUI
Business Manager
Tel: (852) 2648 2822
Email: [email protected]
Acknowledgements
We gratefully acknowledge the support of the following organisations:
(In alphabetical order)
D IAMO ND S PO NSO RS
Karl Storz
Olympus
P LATINUM S PO NSO RS
Novartis
Pfizer
G O LD S PO NSO RS
Associated Medical Supplies
Astellas
Bayer
Beckman Coulter
Caster (HK) Medical Supplies
Cook Medical
Eli Lily
Esaote
Ferring
GlaxoSmithKline
Humane Link
Ipsen
Jacobson Medical
Johnson & Johnson
LF Asia
Lumenis
Medical Distributor Alliance
Newtech
sanofi-aventis
Shun On
Sino Spirit
Synmosa
Takeda
Tristel
Tronda
Acknowledgements
We would like to express sincere appreciation to the
following companies which have contributed to the
success of the Family Physician Symposium: (In
alphabetical order)
Abbott Laboratories Limited
Astellas Pharma Hong Kong Co. Ltd.
Ferring Pharmaceuticals Ltd.
GlaxoSmithKline Ltd.
Pfizer Corporation Hong Kong Ltd.
sanofi-aventis Hong Kong Ltd.